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Abstract 
Protein Kinase C (PKC) has been implicated in many cellular responses. 
Of the 11 isotypes in this family, seven are expressed in B16 mouse melanoma 
cells − PKCα, PKCδ, PKCε, PKCθ, PKCλ, PKCζ, and PKCµ.  
 
Treatment of B16 cells with retinoic acid (RA) results in growth inhibition 
and differentiation. Simultaneously, RA induces a 6-8 fold increase of PKCα 
protein level, but only about 2-fold increase of PKC enzyme activity. The over-
expression of wild type PKCα in B16 cells mimicked the action of RA. The over-
expression of enzymatically inactive PKCα, either open or closed conformation, 
also inhibited B16 cell anchorage-dependent and –independent growth. The 
percent reduction in growth rate correlated with the expression level of 
enzymatically inactive PKCα. The over-expression of enzymatically inactive 
PKCα did not affect the phosphorylation status of other PKC isozymes expressed 
in B16, suggesting that it was not interfering with their functional activity. 
Bisindolylmaleimide, a selective PKC enzyme inhibitor, did not reverse the effect 
of RA on B16 cell growth and differentiation. Cumulatively, these data suggest 
that PKCα has a non-enzymatic function in an RA-mediated cell signaling 
pathway which results in growth arrest and differentiation. 
 
PKCλ and PKCµ protein levels were decreased about 50% after 48h of 
RA treatment. PKCλ protein level was found directly correlating with the growth 
                                                                        vii
  
rate of B16 cells. In order to study the function of PKCλ, the full length mouse 
PKCλ cDNA was cloned and expressed in B16 cells. The anchorage-dependent 
growth rate of B16 cell clones that over-expressed PKCλ was greater than wild 
type cells. These data indicate that PKCλ may be part of a pathway leading to 
enhanced B16 cell proliferation. There are no consistent changes in the levels of 
cell cycle regulatory proteins in B16 cell clones which overexpress PKCλ. 
However, the protein level of cyclin-dependent kinase inhibitors p21 was 
downregulated and p27 upregulated by RA treatment. The p27 protein level was 
increased at 2-h after RA treatment. Future studies need to investigate how p21 
and p27 are regulated by RA, and to elucidate the role of PKCλ in growth control 
using inducible dominant-negative PKCλ constructs.   
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Literature Review 
 
Retinoids 
 
        Retinoid is a generic term for vitamin A and its natural products or 
synthetic analogs. Retinoids are a class of compounds consisting of four 
isoprenoid units joined in a head-to-tail manner. The structure of retinoids can be 
divided into three moieties: a polar terminal end, a conjugated side chain, and a 
β-ionone ring (cyclohexenyl). There are three major endogenous retinoids: retinol, 
retinal and retinoic acid (Figure 1). Retinoic acid is the most biologically active 
form of retinoids. In plants, the carotenoids precursors of Vitamin A are most 
often found in dark orange-colored and yellow-colored fruits and leafy greens. In 
animals, Vitamin A exists as esters in liver, egg yolks, milk and milk products. 
Most retinoids are fat-soluble and retinol metabolites occur in the all-trans 
configuration. The 11-cis aldehyde form, 11-cis retinal, is the chromophore in the 
retina of the eye, and several acid forms such as the all-trans, 3,4-didehydro- and 
9-cis retinoic acids, are biologically active metabolites of retinal found in most, if 
not, all tissues.  
 
Retinol and its derivatives are hydrophobic compounds that are unstable 
in the presence of oxygen and in an acidic environment yield a mixture of 
dehydrated and double-bonded rearranged products. Light also catalyzes 
double-bond isomerization of most retinoids. These properties require that 
 1
  
retinoids be handled experimentally in an inert atmosphere, avoiding contact with 
acids and protected from light. 
 2
  
Figure 1. Structure of retinoids. The upper pannel shows the structure of RA of 
different configuration, all-trans and 9-cis RA. The bottom panel shows the 
convesion between the three forms of retinoids, retinol, retinal, and retinoic acid. 
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Figure 1 
 
              
COOH
9-cis-Retinoic acid  
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Transportation and metabolism 
Mammals, including humans, can not synthesize retinoic acid de novo. 
Vitamin A is absorbed as retinol by hydrolysis of retinyl esters or carotenoids. 
The retinol is absorbed in intestine and stored in liver stellate cells as retinyl 
esters (Blomhoff et al., 1990). When retinol replenishment is required, the retinyl 
ester is hydrolyzed, bound to retinol binding protein (RBP) and released into the 
plasma. During circulation the retinol: RBP (Yamada et al., 1987) form a complex 
with the plasma protein transthyretin, previously referred to as pre-albumin. The 
mechanism of the uptake of retinol from plasma into cells is not fully understood. 
Inside the cells, retinol binds to cellular retinol-binding protein (CRBP) (Godovac-
Zimmermann, 1998). CRBP has two subtypes, CRBPI and CRBPII. CRBPI is 
widely distributed in a variety of different tissues including liver, kidney, lung, 
testis and epididymis (Ong et al., 1982; Porter et al., 1983), while CRBPII is 
localized primarily to the small intestine (Li et al., 1986). CRBPII is thought to 
function as the initial acceptor of retinol entering a target cell. CRBPII has been 
demonstrated to bind the luminal retinol during the process of intestinal 
absorption of vitamin A. 
 
 In the target cells, retinol is converted to retinoic acid by two steps. First, 
retinol is oxidized to retinal, a reaction catalyzed by several different forms of 
alcohol dehydrogenases (Deuster, 1998). In the second step retinal is oxidized to 
all-trans retinoic acid through the action of one of the three related retinaldehyde 
dehydrogenases. This reaction is the rate limiting step in the biosynthesis of all-
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trans retinoic acid. Retinoic acid is bound to the cellular retinoic acid-binding 
protein (CRABP) (Shubeita et al., 1987). The CRABPs protect retinoids in vivo 
from other cellular proteins, transform bound retinoids into specific biological 
compounds, and modulate the concentration of free retinoic acid available to the 
nuclear receptors (Fiorella et al., 1993). There are also two subtypes of CRABP, I 
and II. Both CRABPs specifically bind all-trans retinoic acid and have much lower 
affinity for either retinol or retinal (Jetten and Jetten, 1979; Bailey and Siu, 1988). 
CRABPI has the ability to bind 13-cis retinoic acid while CRABPII can not. 
CRABPII can be induced by retinoic acid. Durand et al. (1992) demonstrated that 
there is a retinoid nuclear receptor binding site in the promoter region of CRABPII. 
CRABPII also may function as a ligand-dependent transcription regulator of the 
RAR signaling pathway in eukaryotic cells (Delva et al., 1999). 
 
Functions and clinical application 
 
        Vitamin A in higher animals has two very different functions, light 
absorption for vision (Wald, 1951) and gene regulation for growth and 
development (Maden, 1994; Hofmann and Eichele, 1994). The retinoid needed 
for vision is the aldehyde isomer 11-cis retinal. RA plays a vital role in normal 
embryonic development. It was shown half a century ago that conceptuses of 
vitamin A-deficient rat displayed a large number of congenital abnormalities, 
including the eyes, myocardium and aorticopulmonary septum, diaphragm, 
respiratory and uro-genital systems (for review, see Wilson et al. 1953). 
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         Epidemiological evidence shows an inverse relationship between vitamin 
A levels and incidence of specific malignancies (reviewed in Hong et al., 1994). 
Retinoids, as anti-cancer agents, have been found to work well in some kinds of 
hematological malignancies, especially acute promyelocytic leukemia, in which 
RA-treatment results in the remission of the malignancy (Chomienne et al., 1996). 
Moreover, retinoids have been used in a number of preclinical and clinical trials 
for treatment and prevention of cancers of the skin, head and neck, lung, breast, 
ovary, and prostate. All-trans RA, 13-cis RA, and the synthetic retinoid N-(4-
hydroxylphenyl) retinamide (4-HPR) have been used as chemo-preventive 
agents for carcinoma in the aerodigestive tract and for the treatment of 
leukoplakia (Lotan, 1994; Lotan et al., 1995; Hong et al., 1995 and 1987). Clinical 
trials reveal that retinoids are active in reducing some second primary cancers. 
For example, 13-cis-retinoic acid reduces the development of primary 
aerodigestive tract tumors in patients with resected head and neck cancers 
(Hong et al., 1990). Retinoids have been successfully used in combination with 
interferon-α-2A, in the treatment of squamous cell carcinoma of the skina or 
cervixb, and renal cell cancer (Lippman et al., 1992 a and b; Motzer et al., 1995).  
 
Despite successful use of retinoic acid, acquired RA resistance is very 
common in patients treated continuously with RA for acute promyelocytic 
leukemia. Vitamin A-associated toxicities limit chronic administration of retinoids 
to individuals at high risk for cancer development (Hong et al., 1986; Hong et al., 
1990). β-carotene, which is well tolerated when administered chronically, is 
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unable to reduce lung cancer in high risk groups in randomized trials (Hennekens 
et al., 1996; Omenn et al., 1996). The resistance to retinoic acid could be due to 
decreased uptake by the cells, increased cytoplasmic sequestration, increased 
cytoplasmic retinoic acid catabolism, decreased nuclear transport, or aberrations 
of RA nuclear receptor-gene response mechanisms (reviewed by Gallagher, 
2002). However the overall clinical efficacy of retinoic acid makes it more 
important to explore the molecular mechanism of retinoic acid as a treatment and 
prevention agent. 
 
Molecular mechanism 
 
        The actions of RA are mediated by two classes of nuclear receptors, both 
of which belong to the nuclear hormone receptor superfamily (Chambon, 1995). 
The two classes of receptors are retinoic acid receptors (RAR) and retinoid X 
receptors (RXR). Both RAR and RXR have three subtypes, α, β, and γ.  Each of 
these is expressed as several different isoforms due to alternative splicing, 
differential promoter usage or use of more than one transcriptional start sites 
(Kastner et al., 1990; Leroy et al., 1991; Leid et al., 1992; Nagpal et al., 1992). 
The distribution of each RAR subtype during embryonic development is different 
(Dolle et al., 1989; Ruberte et al., 1991), which suggests separate functions 
among RARs. 
 
RAR and RXR are ligand-activated transcription factors and share a 
common structure which consists of six domains (designated as A to F from N-
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terminus to C-terminus) (Mangelsdorf et al., 1990; Mangelsdorf et al., 1992; 
Petkovich, 1992). The A and B domains function in ligand-independent 
transcription transactivation domain, while the E domain provides ligand-
dependent transcription transactivation. Both the C and E domains have been 
demonstrated to mediate receptor dimerization (Chambon, 1996). The DNA 
binding domain (C domain) and ligand binding domain (E domain) are highly 
conserved. The hinge region (D domain) and the carboxyl-terminal region (F) are 
variable. The DNA binding domain has two zinc fingers which interact with 
retinoid response elements (RARE) on the target genes (Berg, 1989; Klug and 
Schwabe, 1995). 
 
Members of the nuclear receptor superfamily modulate gene expression 
by binding as homo- or hetero-dimers to specific DNA sequences. RAR functions 
as a heterodimer with RXR; RXR can form homodimers or heterodimers with 
many other nuclear receptors such as the vitamin D receptor (Yu et al., 1991) 
and the Peroxisomal Proliferator Activated Receptors (PPAR) (Kliewer et al., 
1992). The homo- or heterodimers RAR and RXR bind to a specific DNA 
sequence, RARE (retinoic acid receptor response element), found in target 
genes. RARE consists of a direct repeat of PuGGTCA sequences separated by 
one or five nucleotides. The RARs are activated by both all-trans RA and 9-cis 
RA, while RXRs are activated only by 9-cis RA. The human and mouse RARβ2 
isoform gene contains a RARE in its promoter region, so its expression is 
induced by retinoic acid (Mendelsohn et al., 1991). 
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The observation that unliganded RAR and thyroid receptor can strongly 
transrepress target gene transcription led to the discovery of the corepressors, 
such as nuclear receptor corepressor (NcoR) (Seol. et al., 1995) and silencing 
mediator of retinoid and thyroid hormone receptors (SMRT) (Ordentlich et al., 
1999). The corepressors recruit a multiprotein complex with histone deacetylase 
activity that modifies chromatin to prevent transcription (Alland et al., 1997). 
Ligand binding induces a conformational change in the receptor protein which 
causes dissociation of the corepressors and allows coactivators to bind to the 
heterodimers (Chen and Evans, 1995). The coactivators such as CREB-binding 
protein (CBP) and p300 possess histone acetyltransferase activity which 
“relaxes” the chromatin structure allowing for transcription activation of the target 
genes (Chakravarti et al., 1996; Korzus et al., 1998).  This process is illustrated 
in Figure 2. 
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Figure 2. Metabolism, transportation, and molecular mechanism of 
retinoids. When retinol is released into blood, it binds to retinol binding protein 
(RBP) and is uptaken by the cells. In cytoplasm, retinol binds to cellular retinol 
binding protein (CRBP), and is converted to retinoic acid. Retinoic acid binds to 
cellular retinoic acid binding protein (CRABP), is transported into nucleus. In the 
nucleus, retinoic acid binds to retinoic acid receptor: retinoid X receptor (RAR: 
RXR) complex, which dissociates the corepressors from RAR: RXR complex and 
recruits coactivators and histone acetyltransferase, and then turn on the 
expression of the target gene which has a RARE in its promoter. 
 11
  
Figure 2 
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Retinoic acid chemoprevention mechanism  
Although retinoids have been widely studied, some of their actions are not 
yet fully understood. Retinoids inhibit growth of a variety of neoplastically 
transformed cells by growth arrest at the G1 phase of the cell cycle (Wu et al., 
1997), promotion of differentiation (Breitman et al., 1980; Edward et al., 1988), 
and initiation of apoptosis (Mangiarotti et al., 1998). No single common 
mechanism of retinoid action has been identified. Abnormalities of the retinoid 
signaling pathway have been identified as contributing factors to the genesis of 
several human cancers (de Thé et al., 1996). The retinoic acid receptors are 
essential components mediating the anticancer effects of retinoids in some 
malignant cells. Low expression level of RARβ has been found in many 
malignant cells, and the expression of RARβ can be induced by retinoid 
treatment in retinoid-sensitive cancer cells (Sun et al., 2000). Loss of RARβ 
expression is an early feature in the genesis of breast cancer and squamous cell 
carcinoma of lung. Over-expression of exogenous RARβ inhibits growth and 
restores retinoid sensitivity in cervical (Sun et al., 2000), lung (Liu et al., 1996a), 
and breast cancer cells (Geisen et al., 2000). Over-expression of RARα and γ in 
neoplastic epidermal cells causes retinoic acid-induced growth arrest and 
apoptosis (Hatoum et al., 2001). Retinoic acid modulates the cell cycle through 
its ability to modulate the protein levels of various cell cycle regulators. Cell 
progression depends on the complexes composed of cyclins and cyclin-
dependent kinases (cdks). Retinoic acid regulates the activities of cyclin-cdk 
complexes either by destruction of cyclins through ubiquitination (Spinella et al., 
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1999), or by increasing the protein levels of the cdk inhibitors, such as p21, p27, 
and p16 (Zhang et al., 2000; Dimberg et al, 2002; Arany et al., 2003). Retinoic 
acid treatment induces the transcription of p21, which has a RARE in its 
promoter region (Liu et al., 1996b).  There is increased expression of p27 and 
decreased activity of cdk2, cdk4 by retinoic acid treatment in several cancer cell 
lines, including human hepatoma cells (Suzui et al., 2002) and lung cancer (Hsu 
et al., 2000). The up-regulation of p27 by retinoic acid is not at the transcription-
translation level, but rather due to down-regulation of degradation through the 
ubiquitination mechanism (Spinella et al., 1999). Constitutive expression of a 
degradation-resistant mutant of cyclin D1 blocks retinoic acid-mediated growth 
arrest and differentiation of an embryonal carcinoma cell line (Spinella et al., 
1999).  
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Protein Kinase C 
        Protein kinase C (PKC) is a family of homologous protein 
serine/threonine-specific protein kinases which has been implicated as key 
messengers in cell signaling. The PKC family consists of at least 12 isozymes 
which can be divided into 3 subfamilies based on their homology and sensitivity 
to activators. The classical PKCs (α, β1, β2, and γ) require calcium, 
phospholipids, and diacylglycerol (DAG) or phorbol esters for activation. The 
novel PKCs (δ, ε, η, and θ) require phospholipids and DAG/phorbol esters, but 
do not require calcium for activation. The atypical PKCs (ζ and λ) are insensitive 
to DAG, phorbol esters, and calcium, but require phospholipids for activation. 
Finally, PKCµ, part of the PKD family, does not fit into any of these groups. It is 
phospholipid-dependent, calcium-insensitive and activated by phorbol esters. 
However, its catalytic domain is divergent from that of PKC family members. 
 
Structure of PKC   
 
Members of the protein kinase C family consist of a single polypeptide. 
The N-terminal region of the protein contains the regulatory domain and the C-
terminal region contains the catalytic domain. Classical PKCs (cPKC) contain 
four conserved domains C1-C4 (Fig. 3). The C1 domain contains the cysteine-
rich motif (zinc finger motif), duplicated in most isozymes, which forms the 
binding sites for phospholipids and DAG. This domain is immediately preceded 
by the pseudo-substrate (PS) site, which has a high affinity for the active site of 
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the kinase and thereby inhibits enzyme activity by preventing substrate 
interaction. Mutation of this site leads to activation of PKC (Pears et al., 1990). 
The C2 domain is the calcium-binding domain. C1 and C2 together regulate the 
kinase activity. Because of the existence of both C1 and C2 domains in cPKCs, 
the cPKCs respond to phospholipids, phorbol esters and calcium. The C3 and C4 
domains together constitute the catalytic domain, with the ATP-binding site 
located in the C3 domain and the protein substrate recognition site located in the 
C4 domain. The novel PKCs (nPKCs) are structurally similar to the cPKCs, 
except for the C2 domain. This domain in nPKCs maintains the structural 
similarities, but does not have the functional groups that mediate calcium binding. 
Therefore the nPKCs only respond to phospholipids and phorbol esters, but not 
calcium. The atypical PKCs (aPKCs) are structurally quite different from the other 
two subfamilies. First, the C1 domain of aPKCs has only one cysteine rich motif, 
and second, cPKCs lack a C2 domain. Protein kinase Cµ (PKCµ) or its mouse 
homologue protein kinase D (PKD) differs from PKC isozymes by its N-terminal 
signal peptide (SP), transmembrane domain, and pleckstrin homology (PH) 
domain in the regulatory region. The regulatory domain serves two key functions; 
(i) it targets the kinases to the appropriate cellular location; and (ii) it regulates 
kinase activity by serving as an autoinhibitory module. 
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Figure 3. Structure of PKC isozymes. PKC is a single polypeptide. It consists 
of the regulatory domain in the N-terminus, the catalytic domain in the C-terminus, 
and the hinge region between these two domains. The catalytic domain of all 
PKCs has C3 and C4 domains. The conventional PKCs (cPKCs) and novel 
PKCs (nPKCs) have pseudostrate site, C1 domain and C2 domain in the 
regulatory domain. The C1 domain of cPKCs and nPKCs has two cysteine-rich 
motifs. The atypical PKCs (aPKC) have psudosubstrate site and C1 domain in 
the regulatory domain, and the C1 domain only has one cysteine-rich motif. The 
regulatory domain of PKCµ consists of transmembrane domain, peudosubstrate 
site, C1 domain, and pleckstrin homology. N – N-terminus of the protein; C – C-
terminus of the protein; PS – pseudosubstrate site; C – conservative domain; 
SP/TM – signal peptide/transmembrane domain; PH – pleckstrin homology. 
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Figure 3 
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Activation of PKC  
 
PKC activation is regulated by phosphorylation and interaction with 
cofactors. Phosphorylation is important in the activation of PKC family members. 
Full kinase activity depends upon phosphorylation of their catalytic domain 
activation loops. The highly conserved threonine residue in the activation loop 
must be phosphorylated before the kinase can phosphorylate its substrate. The 
phosphorylation of this threonine then leads to the subsequent 
autophosphorylation of serine/threonine at two C-terminal sites: the turn motif 
and the hydrophobic motif, which is roughly about 160 amino acids carboxy-
terminal to the activation loop phosphorylation site (Behn-Krappa and Newton, 
1999; Cenni et al., 2002). The kinase capable of phosphorylating the activation 
loop site in PKC was discovered to be 3-phosphoinositide-dependent kinase 1 
(PDK-1). PDK-1 has been shown to be the upstream activating kinase for 
conventional (Dutil et al., 1998), novel (Le Good et al., 1998; Cenni et al., 2002) 
and atypical (Le Good et al., 1998; Chou et al., 1998) PKC family members. 
PDK-1 was first found to phosphorylate protein kinase B (PKB)/Akt. PKB/Akt 
becomes a substrate for PDK-1 once its PH domain engages PIP3 on the 
membrane, exposing the PDK-1 phosphorylation site. The naming of PDK-1 
reflects the phosphoinositide-dependence of its first known substrate. 
Nonetheless, the phosphorylation of PKC by PDK-1 appears to be 
phosphoinositide-independent (Sonnenburg et al., 2001). The intrinsic activity of 
PDK-1 appears to be constitutive. The fully phosphorylated PKC is competent to 
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be activated by the lipid second messengers. The interaction of DAG with the C2 
domain dissociates the pseudosubstrate sequence from the substrate-binding 
site, and the conformational change allows full enzymatic activity. The unmasking 
of the substrate-binding site allows substrate to bind and become phosphorylated.  
 
Degradation of PKC    
Active PKC is highly sensitive to dephosphorylation. Dephosphorylated 
PKC is ubiquitinated and subsequently degraded in the proteosome (Lee et al., 
1996). Prolonged activation by phorbol esters results in the down-regulation of 
cPKCs and nPKCs through this proteolytic pathway. Atypical PKCs are resistant 
to this phorbol ester-induced down-regulation. 
 
Distribution and Translocation of PKC  
Translocation of PKCs was once taken as the hallmark of PKC activation. 
The localization of PKCs determines their function and specificity. Most PKCs are 
located in the cell cytosol in the inactive state, although individual PKCs have 
their own distribution patterns. PKCα localizes in the cell homogenously and 
translocates to the cell membrane and perinucleus upon activation by phorbol 
esters. Receptor for activated kinase C (RACK) and other PKC binding proteins 
are involved in the determination of the location and substrate specificity of PKC 
isozymes (Mochly-Rosen, 1995). 
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Functions of PKCs    
 
PKCs have been implicated in the control of cell proliferation, 
differentiation, and survival in many tissue types. Abnormal PKC activity is 
involved in cardiovascular, pulmonary, allergic, mental and other disorders. 
However, the specific role of individual PKC isozymes in carcinogenesis is not 
clear. The PKC isozymes may play opposite roles (Mandil et al., 2001). The 
action of the same isozymes in different tissue types may also be different. For 
example, in the intestine, PKCα has been shown to be a key regulator for the 
induction of cell cycle withdrawal of the intestinal epithelium, and expression of 
PKCα is down- regulated in APCmin mouse adenoma and sporadic human colon 
adenocarcinomas (Klein et al., 2000). In contrast, in some human breast 
carcinomas, the expression of PKCα is up-regulated compared to the adjacent 
normal tissues (O’Brian et al, 1989).  
 
Individual PKC isozymes 
 
        Mammalian PKCα consists of 672 amino acids and is about 81 KDa in 
molecular weight. PKCα is ubiquitously expressed, and is activated by stimuli 
such as signals activating tyrosine kinase receptors, physical stresses and 
mechanical strain. Upon stimulation, PKCα translocates from cytosol to specific 
cell compartments, including nuclei, focal adhesions, and regions of cell-cell 
contact (Wagner et al., 2000; Ng et al., 1999). One of the compartments PKCα 
translocates to is the nucleus (Buchner, 1995). Since PKCα does not have a 
nuclear localization signals (NLS), it is unclear how PKCα translocates to the 
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nucleus (Schmalz et al., 1998). As mentioned previously, the isoform-specific 
anchoring proteins (RACK) are important in conducting the isozyme-specific 
localization and different functions. The anchoring proteins responsible for PKCα 
in focal adhesions are vinculin and talin in REF52 cells (Hyatt et al., 1994), and 
β1-integrin in MCF-7 cells (Ng et al., 2001). However, the protein anchoring 
PKCα within the nucleus is not known. PKCα is implicated in many biological 
responses, such as proliferation, apoptosis, differentiation, cell migration, 
adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, and inflammation. 
The biological responses of PKCα are cell-type specific. For example, 
overexpression of PKCα promoted MCF-7 human breast cancer cells to a more 
aggressive phenotype (Ways et al., 1995), while overexpression in human 
intestinal epithelial cells induced withdrawal from the cell cycle (Frey et al., 2000). 
The mechanism of PKCα action is not very clear. The proliferative effect of PKCα 
appears to be related to the activation of the extracellular signal-regulated 
kinase/mitogen-activated protein kinase (ERK/MAPK) cascade initiated by Raf-1 
(Kolch et al., 1993). The cell cycle arrest mediated by PKCα may be due to the 
accumulation of retinoblastoma protein (Rb) and induction of the cyclin 
dependent kinase inhibitors, p21Cip1 and p27Kip1(Slosberg et al., 1999; Frey et 
al.,1997; Frey et al., 2000). 
 
       The PKCβ gene generates two proteins, PKCβI and PKCβII, by alternative 
splicing of the C-terminal exons (Ono et al., 1987).  PKCβI and PKCβII are 
mainly involved in the immunoreceptor and insulin receptor signaling pathways 
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(reviewed by Kawakami et al., 2002). PKCγ is exclusively expressed in the 
central nervous system. PKCγ is implicated in long term depression and other 
mental disorders (reviewed by Saito and Shirai, 2002). PKCθ is expressed at 
high levels in T lymphocytes and muscle. PKCθ plays essential roles in T cell 
activation and the T cell receptor-linked signaling pathway mediating T cell 
activation (Altman et al., 1990; Isakov and Altman, 2002). PKCε regulates 
various physiological immune functions. PKCε is also implicated in some disease 
states including malignancies, diabetes, cardiac ischemia, and Alzheimer’s 
disease (reviewed by Akita, 2002). PKCδ seems to be linked to proliferation 
control. Overexpression of PKCδ results in growth arrest of cancer cells 
(Watanabe et al., 1992; Fukumoto et al., 1997), and apoptosis of prostate cancer 
cells (Sumitomo et al., 2002). The expression of PKCη is also tissue-specific; it is 
expressed predominantly in squamous epithelia, including skin, tongue, 
esophagus, forestomach, trachea and bronchus. The expression level of PKCη 
increases with differentiating or differentiated cells, and overexpression of PKCη 
results in the hyperdifferentiation of squamous cells. Therefore, PKCη plays a 
crucial role in squamous cell differentiation (Denning et al., 1995; Kuroki et al., 
1999). 
 
        Although PKC isozymes are widely involved in cell responses in a cell-
type specific, temporal and spatial manner, surprisingly PKC isozyme knockout 
mice appear to be functionally normal in regard to external characteristics, 
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viability and fertility (Leitges et al., 2002). The only exception is the PKCλ 
knockout mouse, which is embryonic lethal.   
 
       PKCλ was first cloned by Dr. S. Ohno’s group in 1994 (Akimoto et al., 
1994). PKCλ bears a high similarity (72%) in amino acid sequence with another 
member of aPKCs, PKCζ.  PKCι, which has 98% identity with PKCλ, is the 
human homologue of murine PKCλ. Due to its N-terminal structure, PKCλ, like 
PKCζ, is insensitive to calcium, DAG, and phorbol esters in vitro and in vivo. 
However it can be directly activated by lipid second messengers, such as 
ceramide, PIP3, and phosphatidic acid. Unlike the cPKCs and the nPKCs, 
aPKCs contain glutamic acid instead of the second autophosphorylatable serine 
in the C-terminal hydrophobic motifs (Newton, 2001).  It has been shown that 
PKCλ is involved in embryogenesis and other physiological processes including 
glucose transportation and growth. There are several proteins that interact with 
PKCζ and modify its action (Figure 4).  Several proteins that interact with the V1 
region of aPKCs share a small acidic stretch called AID (atypical PKC-interacting 
domain). These proteins are p62, Par-6 (partitioning-defective-6), and MEK5. 
The selective aPKC binding protein, p62, bridges PKCλ with RIP, which is a 
scaffold protein in the tumor necrosis factor-α (TNFα) signaling pathway. Thus 
PKCλ is involved in the transduction of TNFα signaling, which leads to the 
activation of nuclear factor-κB (NF-κB) (Sanz et al., 1999). The α isoform of the 
kinase MEK5, which interacts with aPKCs through its AID, brings aPKC into the 
control of cell growth by regulating its downstream kinase BMK1/Erk5 (English et 
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al., 1998; Kamakura et al., 2000). Par-6 is one of the conserved cell polarity 
proteins named after a C. elegans partition defective mutant. The PKCλ-Par6 
complex interacts with Par3, an aPKC specific interacting protein (ASIP), which 
also interacts with the C-terminus of a transmembrane component of the tight 
junction, thereby controlling cell polarity (Ebnet et al., 2001; Suzuki et al., 2001). 
The expression level of PKCλ is high in undifferentiated cells, and then 
decreases with cell differentiation. There is also evidence that PKCλ is a pro-
survival factor. Over-expression of the von Hippel-Lindau tumor-suppressor 
protein increases the ubiquitination of PKCλ, leading to the down-regulation of 
PKCλ (Okuda et al., 2001). Also the induction of cyclin D1 by oncogenic Ha-Ras 
requires PKCλ. Another PKCλ interacting protein, Par-4 (prostate androgen 
response-4), is an inhibitor of PKCλ activity. Overexpression of Par-4 causes 
cells to undergo apoptosis as a result of its ability to inhibit aPKC activity (Diaz-
Meco et al., 1996). Despite their similarity in amino acid sequence, the functions 
of PKCλ/ι and PKCζ are not redundant. PKCζ knockout mice are viable showing 
impaired NF-κB signaling and immune responses, while PKCλ/ι knockout mice 
die at an early embryonic stage (Leitges et al., 2001; Martin et al., 2002). 
Lambda interacting protein (LIP) has shown specifically to interact with the zinc 
finger domain of PKCλ/ι, but not PKCζ (Diaz-Meco et al., 1996). This interaction 
stimulates PKCλ kinase activity following the mitogen stimulation of quiescent 
cells. 
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Figure 4. Protein kinase Cλ structure and physiological function mediated 
by interacting proteins. PKCλ binds to Par-6 (partitioning-defective-6) and the 
PKCλ-Par6 complex interacts with Par3. The PKCλ-Par6-Par3 complex and 
involved in cell: cell junctional structure and the establishment of cell polarity. 
Through interaction with p62, PKCλ is involved in the TNFα (tumor necrosis 
factor α) signaling pathway, and the following activation of nuclear factor-κB (NF-
κB). The interaction with MEK, brings PKCλ in the MAPK signaling pathway. LIP 
(lambda interacting protein) activates PKCλ activity and Par-4 (prostate androgen 
response-4) inhibits PKCλ activity. 
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Figure 4 
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Melanoma 
 
        Skin cancer is the most common malignancy and accounts for half of 
the newly diagnosed cancers in the western population. The incidence of skin 
cancer has risen significantly in the last decade. There are three kinds of human 
skin cancer: malignant melanoma, basal cell carcinoma and squamous cell 
carcinoma. Melanoma is the least common skin cancer, accounting for about 4% 
of all skin cancer. However, it has the highest mortality of all the skin cancers. In 
2002, among the 1.3 million Americans who were diagnosed with skin cancers, 
56,000 individuals had melanoma, and 7,000 people died of melanoma (Geller, 
2003). The annual incidence rate of melanoma in fair-skinned populations has 
increased about 3-7% in the last decades (Pollock and Trent, 2000; Severi et al., 
2000; Deipgen and Mahler, 2002). Risk factors for melanoma include family 
history, severe blistering sunburn, especially before the age of eighteen, fair skin, 
precancerous lesions, previous melanoma, and exposure to ultraviolet radiation. 
Epidemiological studies show that exposure to UV radiation is the most 
significant risk factor for cutaneous melanoma (Elwood and Gallagher, 1994). 
Sunburn experienced during childhood and adolescence has greater effect on 
melanoma incidence than sunburn at a later age (Østerlind, 1992; Zanetti et al., 
1992). 
 
Over 90% of primary melanoma originates in the skin. The cutaneous 
melanoma arises from a melanocytic nevus which is a benign tumor of the 
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pigment producing cells in the skin. The melanocytic nevus progresses to 
dysplastic nevus, which is considered as the pre-malignant lesion. The dysplastic 
nevus progresses to first a radial growth phase and then the vertical growth 
phase of localized malignant melanoma. The frequent metastatic sites of 
melanoma are lungs, brain and liver. Chromosome alterations have seen 
identified in melanomas (Newton, 1997). 
 
Genetics of cutaneous melanoma 
 
        For most cancer, tumorigenesis is a multi-step process, involving the up-
regulation of oncogenes and down-regulation of tumor suppressor genes. Recent 
melanoma research has identified the cytogenetic and genetic alterations 
responsible for the development and progression of this tumor. There are a 
number of oncogenes reported to be involved in the transformation to malignant 
melanomas. These genes include the signal transducers ras (Papp et al., 1999; 
Bastian et al., 2000), b-raf (Davies et al., 2002; Pollock et al., 2003), cyclinD1 
(Sauter et al., 2002), cdk4 (Zuo et al., 1996), c-myc (Kraehn et al., 2000), and 
hdm2 (Polsky et al., 2002), growth factors bFGF (Meier et al., 2000) and 
MGSA/GRO (Owen et al., 1997), and the inhibitors of apoptosis bcl-2 and bcl-
xL(Leiter et al., 2000).  Demunter et al (2001) reported N-Ras mutations in 33% 
of primary and 26% of metastatic clinical melanoma samples. About 66% of 
melanomas have a b-raf mutation (Davies et al., 2002). Raf can be activated by 
ras, and it in turn activates the MAPK/ERK pathway. Point mutations of B-raf 
often seen in melanoma increase its kinase activity and then activate the MAPK 
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pathway, which confers the growth advantage to melanoma cells. Amplification of 
cyclin D1 has been identified mostly in acral melanoma (Sauter et al., 2002). 
Point mutations of Cdk4 interfere with its binding to p16, the cell cycle kinase 
inhibitor which itself is often found mutated in familial melanomas (Cannon-
Alright et al., 1992). Disruption of the function of tumor suppressor genes also 
contributes to the process of oncogenesis. The tumor suppressor genes altered 
in melanoma are PTEN and p53. PTEN, located at chromosome 10, is a gene 
deleted or mutated in more than 40% of melanoma cell lines and melanoma 
specimens (Guldberg et al., 1997). PTEN encodes a phosphatase which 
degrades the products of PI3K by dephosphorylating phosphatidylinositol-3,4,5-
triphosphate (PIP3) and phosphatidylinositide 3,4-bisphosphate at the 3 position 
(Simpson and Parsons, 2001). Loss of functional PTEN in tumor cells causes an 
increase in Akt phosphorylation and activity, leading to decreased apoptosis 
(Kennedy et al., 1997; Kulik et al., 1997). Restoration of normal PTEN expression 
by transferring chromosome 10 into a PTEN-null malignant melanoma cell line, 
retarded the tumor cell growth (Stahl et al., 2003). The loss of heterozygosity of 
p16, a cell cycle inhibitor, may be one of the earliest events in melanoma 
development, as the deletion is detected in invasive primary lesions with thin 
tumor thickness (Healy et al., 1996; Rocco and Sidransky, 2001). 
 30
  
Experimental Objectives 
This dissertation addresses the role of PKC isozymes in retinoic acid-
induced B16 mouse melanoma cell growth arrest and differentiation. Previous 
studies from this laboratory have shown that PKCα is important in RA-induced 
B16 cell growth arrest and differentiation. I investigated the requirement for PKCα 
enzyme activity for mediating RA-induced B16 cell growth arrest and 
differentiation. The first part of this dissertation describes experimental results 
which address the role of PKCα. 
During the study on the first part of my thesis dissertation, I discovered 
that PKCλ was down-regulated by RA treatment. I also found that expression of 
PKCλ correlates with B16 cell growth rate. The second part of this thesis is 
focused on the role of PKCλ in the regulation of B16 cell growth. Lastly I 
determined whether RA inhibits cell proliferation by altering the expression of cell 
cycle regulatory proteins.  
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Chapter Ι 
Non-enzymatic function of PKCα in 
retinoic acid-induced growth arrest 
and differentiation 
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Introduction 
 
 
      Retinoids have been shown to induce growth arrest and differentiation in a 
variety of tumor cell lines, including B16 mouse melanoma (Breitman et al., 1980; 
Meyskens and Fuller, 1980; Wu et al., 1997). In this mouse melanoma cell line, 
RA induced a 5-8-fold increase in PKCα expression (Niles and Loewy, 1989). 
Overexpression of wild-type PKCα in B16 cells mimicked the phenotype induced 
by RA, including inhibition of anchorage-dependent and –independent growth 
and increased melanin production. Down-regulation of PKC by chronic phorbol 
dibutyrate treatment antagonizes the ability of RA to induce growth arrest and 
differentiation. These data suggest that PKCα plays a critical role in mediating 
the effect of RA on B16 melanoma cells. However, we show here that the PKC-
selective inhibitor, bisindolylmaleimide, does not block the action of RA on B16 
cells. Thus it appears that PKCα might have a non-enzymatic function in the 
regulation of melanoma growth. To test this hypothesis, we used two types of 
PKCα mutants (Figure 5). Both have a mutation at the ATP-binding site which 
inactivates the enzyme activity. One also has additional mutations in the pseudo-
substrate site. This mutation prevents binding of the substrate recognition 
domain and hence results in a mature “open” conformation. Normally it would 
yield a constitutively active PKCα. However, the mutation at the ATP-binding site 
prevents catalytic activity. When transfected into cells, this enzymatically inactive 
mutated PKCα will compete with the endogenous PKCα for its substrates and 
thus prevent the phosphorylation of PKCα substrates. Therefore, overexpression 
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of mutant PKCα inhibits the function of endogenous PKCα. I will report in my 
thesis that stable expression of these mutant PKCα proteins recapitulates some, 
but not all, of the phenotypic changes found in retinoic acid treated wild type B16 
melanoma cells. 
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Figure 5. Structure of dominant-negative PKCα.  Both PKCα mutants have 
mutation at the ATP-binding site, which inactivates the PKCα. The PKCα mutant 
with the only mutation at the ATP-binding site mimics the structure of inactive 
PKCα and is designated as closed-conformation. When PKCα is fully activated 
through phosphorylation and cofactor-binding, the pseudo-substrate site 
dissociates from substrate-binding site. The two additional single mutations at the 
pseudo-substrate site dissociate the pseudo-substrate site from the substrate 
binding site; therefore the conformation of this PKCα mutant mimics that of the 
active PKCα. This PKCα mutant with additional mutations is designated as open-
conformation.  A - alanine, K -  lysine,  P – phosphate group, and R - arginine. 
 35
  
Figure 5 
 36
  
 
 
Materials and Methods 
 
 
    Cell Culture: B16 mouse melanoma cells were cultured in a humidified 
atmosphere of 5% CO2, 95% air at 37°C in Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco, Grand Island, NY). This medium contained 1 g/l glucose and 
was supplemented with 10% bovine calf serum (Hyclone, Logan, UT) for most of 
the experiment or 10% fetal bovine serum for growth studies in comparison with 
stably transfected clones, 50 units/ml penicillin G, and 50 µg/ml streptomycin 
sulfate. All the stably transfected clones were grown in DMEM medium 
supplemented with 10% fetal bovine serum. 
   Reagents: All the reagents used in this research were obtained from 
Sigma (St. Louis, MO) if not stated otherwise. The retinoic acid all-trans-RA was 
obtained from Fluka Chemical Company (New York). All experiments involving 
the use of RA were conducted in yellow light to prevent photo-oxidation of the 
retinoids and the RA in each experiment was freshly made. Retinoic acid, 
bisindolylmaleimide, and phorbol-12, 13-dibutyrate were dissolved in dimethyl 
sulfoxide (DMSO) and handled in yellow light. DMSO was used as the vehicle 
control. Transfer buffer was 2.5% (w/v) Tris, 1.44% Glycine, 0.1% SDS, and 20% 
(v/v) methanol. TBS was 20 mM Tris pH 7.6, 0.137 M NaCl, and 0.1% Tween-20. 
Electrophoresis running buffer was 1.44% Glycine, 0.3% Tris-base, and 0.1% 
SDS. LB (Luria-Bertani) medium (1.0% Tryptone, 0.5% Yeast Extract and 1.0% 
NaCl) was dissolved in deionized water, the pH  was adjusted to 7.0 with NaOH, 
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and the solution was autoclaved for 20 minutes at 15 lb/sq. inch, after which 
ampicillin was added to bring the final concentration to 50 µg/ml. For LB agar 
plates, LB medium was prepared as above, with the addition of 15 g/L agar 
before autoclaving. After sterilization by autoclaving, ampicillin was added as 
above, and the solution was then poured into 100 mm plates. When the agar was 
solidified, the plates were inverted and stored at 4°C. 
Transformation: 5-10 ng of plasmid DNA or 2 µl of cloning reaction was 
used for transformation. DNA was introduced into competent E.coli cells by heat 
shock at 42°C for exactly 30 seconds. The competent cells were purchased from 
Invitrogen Life Technologies (Carsland, CA). SOB medium was added to the 
mixture, and the mixture was rocked at 37ºC for 1 h. The mixture was spread 
onto agar plates and incubated at 37ºC overnight. Six colonies were picked, 
inoculated into LB medium and incubated at 37ºC for overnight. 
Plasmid DNA isolation:  Plasmid DNA was isolated using Mini-prep 
Kits from Eppendorf (Brinkmann Instruments, New York) using the company’s 
protocol. Briefly, transformed cells were pelleted and then solutions I, II, III were 
added sequentially. Supernatant was collected and transferred to a column. DNA 
was bound to the binding matrix and after washing the column to remove 
contaminants, the DNA was collected in the elution buffer. The purity and 
concentration of isolated DNA was determined by UV absorbance using 
spectrophotometry (Beckman Coulter, Somerset, NJ). An OD260/280 ratio over 
1.8 was considered acceptable quality of the DNA. 
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    Stable Transfection of B16 Cells:  B16 cells were co-transfected with 
the PKCα mutant with single mutation, SRD-PKCα-Kn (K365R) expression 
vector (YK539) or PKCα mutant with additional mutations, SRD-PKCα-Kn-
R22A/A25E) expression vector (YK563) and the pSV40-neo plasmid encoding 
the gene for neomycin resistance at a 1:10 ratio (pSV40-neo: YK539/YK563). 
The day before the transfection, B16 cells were seeded at 0.8 million per dish. 
Transfection was accomplished by using Lipofectamine plus reagent (Invitrogen 
Life Technologies). For each 100 mm plate, 4 µg of DNA were diluted in 750 µl of 
serum free DMEM, 20 µl of Plus Reagent was added to the DNA and mixed 
(precomplexed DNA). The precomplexed DNA was then incubated at room 
temperature for 15 minutes. At mean time, 30 µl of Lipofectamine Reagent was 
diluted in 750 µl of serum free DMEM, which was combined with the 
precomplexed DNA. This DNA-Plus-Lipofectamine Reagent complex was 
incubated at room temperature for 15 minutes. Plates of B16 cells were washed 
with PBS to remove residual medium and 5 ml of serum free DMEM added. The 
DNA-Plus-Lipofectamine Reagent complex was added to each plate. The plates 
were incubated at 37°C, 5% CO2 for 5 hours. After the 5-hour incubation, the 
volume of medium of each plate was increased to 10 ml and fetal bovine serum 
was added to bring the final concentration to 10%.  Neomycin-resistant clones 
were selected in DMEM containing 1.43 mg/ml of the neomycin derivative G418 
(Gibco BRL Life Technologies, Rockville, MD). 
    Western Blot Analysis:  Cells were seeded at 2x105 /100mm dish. 
After attachment (overnight), cells were refed with DMEM containing 10% fetal 
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bovine serum with or without 10 µM RA and incubated for forty eight hours, 
followed by addition of lysis buffer (62.5 mM Tris (pH 6.8), 2% w/v sodium 
dodecyl sulfate (SDS), 10% glycerol, 50 mM DTT, 0.1% w/v bromphenol blue, 1 
µg/ml leupeptin, 1 µg/ml pepstatin, 50 µg/ml aprotinin, 0.5 mM 
phenylmethylsulfonyl fluoride, and 0.5% Triton X-100).  Cell lysates were 
sonicated for 10 seconds with a Tekmar sonic disruptor (Tekmar Corp., 
Cincinnati, OH) at power setting 60. Cell lysates were centrifuged at 14,000 rpm 
for 5 minutes. Proteins were denatured at 100°C for 2 minutes. Equal volumes of 
cell lysates were loaded into wells and electrophoretically separated on a 10% 
SDS polyacylamide gels. Proteins were electrically transferred to a Hybond-C 
Extra nitrocellulose membrane (Amersham). Membranes were incubated for 1 
hour in blocking buffer (5% nonfat dry milk in Tris-buffered saline containing 0.1% 
Tween (TBST)).  The primary antibody was diluted in blocking buffer. The dilution 
for monoclonal anti- PKCα and -PKCδ antibodies (Upstate Technology, Lake 
Placid, NY) was 1:3000. The dilution for monoclonal anti-PKCε, -PKCη -PKCλ, 
and PKCζ antibodies (Transduction Laboratories) was 1:400. The incubation time 
for these antibodies was 3 hours. The dilution for anti-GAPDH antibody was 
1:5000, and the incubation time was 1 hour. The dilution for anti-Erk1/2, anti-p38, 
anti-phosphorylated-Erk1/2, anti-phosphorylated-p38, anti-phosphorylated-PKCα, 
anti-phosphorylated-PKCδ, anti-phosphorylated-PKCλ, anti-phosphorylated-
PKCζ, anti-PKCµ, and anti-phosphorylated-PKCµ antibodies (Cell Signaling 
Technology, Beverly, MA) was 1:1000. All the antibodies from Cell Signaling 
were polyclonal antibodies and the incubation was at 4°C and overnight. Blots 
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were washed 3 times in TBST, followed by an hour incubation with a 1:3000 
dilution of rabbit anti-mouse horseradish peroxidase-conjugated secondary 
antibody (Amersham Biosciences, Piscataway, NJ) for monoclonal primary 
antibody, or goat anti-rabbit horseradish peroxidase-conjugated secondary 
antibody (Cell Signaling Technology, Beverly, MA) for polyclonal primary 
antibody. Membranes were washed 3 times in TBST after incubation with 
secondary antibody. Reactive bands were visualized by the enhanced 
chemiluminescence method (Amersham Biosciences). All washes and 
incubations were performed at room temperature except mentioned otherwise. 
The density of each band was measured by a laser scanning densitometer 
(Molecular Dynamics, Sunnydale, CA). 
    Enzyme Activities of Partially Purified PKC:  This assay system 
utilizes synthetic, PKC-specific, substrate peptides which become 
phosphorylated with the radiolabeled phosphate group from [γ-32P]ATP.Culture 
conditions were the same as those described for Western blot. Cell were lysed 
on ice with 20 mM Tris, pH 7.5, 2 mM EDTA, 1 mM dithiothretol, 5% Triton X-100, 
0.5 mM phenylmethylsulfonyl fluoride, and 10 µg/ml aprotinin. Complete cell 
disruption was further ensured by three consecutive 10-s sonication with a 
Tekmar sonic disruptor at power setting 60. The total cell lysate was centrifuged 
at 12,000xg for 15 min. The supernatant was loaded onto a DEAE-cellulose 
anion exchange column, which was made by packing Cellex-D cellulose (Bio-
Rad Laboratories, Hercules, CA) into a 1 ml syringe. The column was pre-
equilibrated with column buffer (20 mM Tris, pH 7.5, 2 mM EDTA, 0.5 mM EGTA, 
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1 mM dithiothretol). The column was washed with 15 volumes of column buffer 
containing 100 mM NaCl and the eluate concentrated with a Centricon-30® 
microconcentrator (Millipore, Billerica, MA). Protein concentration of samples was 
determined by the Bradford method.  Samples were diluted to equal protein 
concentrations and assayed with a commercially available PKC assay kit 
(Amersham Biosciences).  The reaction was initiated by addition of 25 µl of 
protein sample to a reaction mixture containing 3 mM calcium acetate, 50 mM 
Tris-HCl, 0.5% (w/v) sodium azide (pH 7.5), 0.075 mg/ml Lα--phosphatidyl-L-
serine, 6 µg/ml phorbol 12-myristate 13-acetate, 225 µM peptide substrate, 7.5 
mM dithiothretol, 200 µM magnesium [γ-32P]ATP (Amersham Biosciences), 12 
mM magnesium chloride (pH 7.4),  and 5 mM Hepes in a total volume of 25 ml. 
After incubation for 15 min at 37°C, reactions were stopped by adding 300 mM 
orthophosphoric acid. Aliquots of the reaction mixtures were spotted onto the 
binding paper discs, and the discs were washed twice for 5 min in 75 mM 
orthophosphoric acid for 5 min. At the end of the reaction, the radiolabeled 
peptide was separated from unincorporated 32P by the use of an affinity paper for 
the peptide. The degree of phosphorylation was determined by liquid scintillation 
counting. Enzyme activity was calculated from counts/min taking into account the 
specific activity of the radioisotope and reaction time. PKC activity was 
expressed as 32P incorporated /min/mg protein. 
    Monolayer Growth Curves:  Cells were seeded at a density of 2.8 x 
104 cells/60mm tissue culture dish (Falcon, Franklin Lakes, NJ) in 3.6 ml of 
DMEM containing 10% fetal bovine serum. The medium was changed on the 
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second day and 10 µM retinoic acid or vehicle was added at this time. For 
experiments using PDB, cells were pre-treated with PDB for 24 h and then RA 
was added to the medium. RA was handled in yellow light at all times. Cells were 
incubated at 37°C in 5% CO2, 95% air. At 24 h intervals, cells were harvested by 
trypsinization, and cells were counted with a hemacytometer. 
    Colony Formation in Soft Agarose:  A 3 ml bottom layer of freshly 
prepared 1% agarose/DMEM/10% fetal bovine serum containing the appropriate 
RA concentration was dispensed into 60 mm dishes and allowed to solidify. The 
top layer consisted of 5000 cells suspended in 3 ml of 0.3% agarose/DMEM/10% 
fetal bovine serum containing the respective RA concentration. Following 
solidification of the top layer, a 2.5 ml DMEM/10% serum liquid overlay, 
containing the appropriate RA concentration, was added to each dish. For 
experiments using PDB, B16 cells were pre-treated with PDB while grown as 
monolayer for 24 hours and then transferred to the top layer of agarose. The 
liquid phase +/− various treatments was changed every 48 h. Viable colonies 
were counted 10 days after seeding. Only colonies greater than or equal to 300 
µm in diameter were counted. 
Melanin Content of Media and Cells:  Cells were seeded into 60 mm 
dishes at different densities based on their growth rate so that after 4 days of 
growth their densities would be similar. After attachment, cells were refed with 
DMEM +/- 10 µM RA. Exactly 3.6 ml medium was added to each dish. Forty-
eight hours after the treatment, 1.5 ml aliquots of medium were taken from each 
dish and centrifuged at 12,000 × g for 10 sec. The relative melanin contents of 
 43
  
supernatants were determined by measuring the absorbance at 462 nm. 800 µl 
of 1 N KOH were added to each dish. Cell lysates were collected and incubated 
at 80°C for 1 h. The hydrolysates were centrifuged at 12,000 x g for 10 sec. The 
relative melanin concentrations of the cleared lysates were determined by 
measuring the absorbance at 462 nm. 
AP-1 Transcriptional Activity:   Wild type B16 cells or PKCα mutant-
expressing clones  were co-transfected with  the reporter plasmid 3.8 µg of pGL-
2-AP-1 DNA and 0.2 µg of SV40-β-galactosidase  DNA, to correct for 
transfection efficiency. The second day after transfection, cells were split and 
seeded at equal density into multi-well plates. After the attachment, cells were 
treated with or without 10 µM RA for 24 h. Cells were then harvested and 
assayed for luciferase and β-galactosidase activity using kits from Promega 
(Madison, WI). The luminescence was measured using a Lumat (Model: LB9501, 
Wallac Inc. Gaithersburg, MD). 
Statistical analysis: Statistical analyses were performed using one way 
ANOVA in SigmaStat™ statistical software (Jandel Scientific; San Rafael, CA). 
Statistical significance was judged at the p<0.05 level. 
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Results 
 
Previous work in our laboratory has shown that treatment of B16 mouse 
melanoma cells with retinoic acid results in at least a 6-8 fold increase in PKCα 
mRNA and protein (Rosenbaum and Niles, 1992). Ectopic overexpression of 
wild-type PKCα in B16 cells results in a phenotype (decreased anchorage-
dependent, -independent growth and increased melanin production) that mimics 
treatment with retinoic acid (Niles and Combs, 1996). Interestingly, treatment of 
these PKCα overexpressing clones with phorbol dibutyrate did not further 
enhance the phenotypic change that mimicked retinoic acid treatment. Therefore 
I investigated whether PKC enzyme activity was required for the phenotypic 
changes induced by retinoic acid in B16 melanoma cell.  
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Effect of PKC enzyme inhibitor bisindolylmaleimide on B16 cells:  Figure 6 
shows that combining bisindolylmaleimide, a PKC enzyme inhibitor (with higher 
specificity for conventional PKCs such as PKCα) with retinoic acid did not alter 
the ability of this retinoid to inhibit anchorage-dependent (Figure 6A) and –
independent growth (Figure 6B) when compared to cells treated only with retinoic 
acid. RA alone induced a 50% decrease in B16 cell anchorage-dependent 
growth at 48 h. Bisindolylmaleimide and RA together induced a further decrease 
(30% to 60%) in growth compared to RA alone.  Interestingly, treatment of B16 
cells with only the PKC enzyme inhibitor resulted in a dose-dependent inhibition 
of proliferation and soft agarose colony formation (anchorage-independent 
growth) compared to untreated control cells (Figure 6B). Similarly, inhibition of 
PKC enzyme activity alone increased melanin production and did not interfere 
with the ability of retinoic acid to stimulate melanin production (Figure 6C). 
Indeed, the combination of retinoic acid and 2.5 µM bisindolylmaleimide resulted 
in an additive stimulation of melanin production. 
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Figure 6. Requirement of PKC enzyme activity for RA-induced inhibition of 
anchorage-dependent, -independent growth and stimulation of melanin 
synthesis. B16 cells were treated with various agents and growth or melanin 
levels were measured as described below. A. Anchorage-dependent growth. 
Cells were seeded in 60 mm tissue culture dishes at 2.8 × 104/dish. One day 
after seeding, cells were refed with growth media containing the indicated 
concentrations of RA, bisindolylmaleimide, or a combination of these two agents. 
After 48-h of incubation, cells were enumerated using a hemacytometer. The 
data are expressed as the mean +/- SEM of triplicate dishes. B. Anchorage-
independent growth. Colony formation in soft agarose was performed as 
described in the Methods. All layers contained the indicated concentrations of RA, 
bisindolylmaleimide, or a combination of these two agents. After 10 days of 
incubation, colonies greater than or equal to 300 µm were counted. The data are 
presented as the mean +/- SEM of triplicate dishes of cells in soft agarose. No 
colonies were formed in the presence of 100 nM bisindolylmaleimide + 1 pM RA. 
C. Melanin production. B16 cells were treated with the indicated concentrations 
of RA, bisindolylmaleimide, or a combination of these two agents. After 48-h of 
incubation, cells were harvested for cell counts and measurement of intracellular 
melanin as described in the Methods. The data are presented as the mean +/- 
SEM of triplicate dishes of cells. These experiments were repeated twice with 
similar results. * - comparison between control and Bis alone, †  - comparison 
between RA and RA+Bis. (* P<0.001, † P<0.001)) 
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Expression of total and phosphorylated PKCα protein in B16 cells: We also 
measured the in vivo activation of PKCα in control and retinoic acid-treated B16 
cells by using an antibody that specifically recognizes phospho-Thr638, a site 
that is autophosphorylated. While retinoic acid induced an 11-fold increase in 
total PKCα, it only induced a 2-fold increase in phospho-Thr638PKCα (Figure 7). 
This agrees with our previous work in which we found that retinoic acid only 
induced about a two-fold increase in the phosphorylation of the MARCKS protein. 
Thus there is a large amount of enzymatically inactive PKCα in retinoic acid-
treated B16 mouse melanoma cells.  
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Figure 7. Effect of RA on total PKCα protein level vs. amount of 
phosphorylated PKCα. B16 cells were treated with 10 µM RA for 48h and then 
prepared for Western Blotting as described in Methods. Replicate blots were 
incubated with either antibody against total PKCα protein (Upstate Technology) 
or antibody that specifically recognizes phosphorylated thr638 PKCα (Cell 
Signaling), an indicator of the amount of enzymatically active PKC. The bottom 
half of each blot was incubated separately with antibody against GAPDH to 
correct for protein loading and specificity of RA-induced changes. Following 
development of the signals by chemiluminescence, the relative amount of total 
and phosphorylated PKCα was determined by densitometry with correction for 
the relative amount of GAPDH in each sample. This experiment was repeated for 
two additional times with similar results. C – control, RA – RA treated. 
 52
  
Figure 7 
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Effect of phorbol dibutyrate on B16 cells: In contrast to the effect of inhibition 
of PKC enzyme activity, down-regulation of PKC by pre-incubation of B16 cells 
with phorbol dibutyrate for 24-h prior to addition of retinoic acid, stimulated cell 
growth and antagonized the ability of retinoic acid to inhibit cell proliferation (Fig. 
8A). Compared to control, PDB treatment increased cell numbers by 40%, 48-h 
of RA treatment caused a 50% decrease in cell number, and PDB and RA 
together resulted in a 17% increase in cell number. PDB also enhanced 
anchorage-independent growth and interfered with the ability of retinoic acid to 
decrease colony formation in soft agarose (Fig 8B). Compared to control, 10 pM 
of RA treatment induced an 80% decrease of colony formation in soft agarose, 
100 nM PDB treatment alone caused a 2-fold increase, and RA and PDB 
treatment together resulted in a significant increase in colony formation. As 
previously reported (Niles et al., 1996), down-regulation of PKC via chronic 
phorbol dibutyrate treatment inhibited melanin production and antagonized the 
ability of retinoic acid to stimulate melanogenesis (Fig. 8C). Compared to control, 
PDB treatment induced a 40% and 50% decrease of medium and cellular 
melanin production respectively. PDB antoganized RA induced increase of 
melanin production. Melanin content in RA+PDB treated cells were significantly 
lower than the control, and not significantly different from PDB treated.  
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Figure 8. Phorbol dibutyrate antagonizes the biologic effects of RA on B16 
melanoma cells. B16 cells were treated with various agents and growth or 
melanin production was measured as described below. A. Anchorage-dependent 
growth. Cells were seeded in 60 mm tissue culture dishes at 2.8 × 104/dish. One 
day after seeding, cells were refed with growth media containing the indicated 
concentrations of RA, phorbol dibutyrate, or a combination of these two agents. 
In the latter case, phorbol dibutyrate was pre-incubated with the cells for 24-h in 
order to down-regulate PKCα before the addition of RA. After 48-h of incubation, 
cells were enumerated by hemacytometer counting. The data are expressed as 
the mean +/- SEM of triplicate dishes of cells. B. Anchorage-independent growth. 
Colony formation in soft agarose was performed as described in Methods. All 
layers contained the indicated concentrations of RA, phorbol dibutyrate, or a 
combination of these two agents. In the combination treatment, cells were pre-
treated with 100 nM phorbol dibutyrate in monolayer culture for 24-h before 
placing cells in the suspension culture with the RA+PDB combination. After 10 
days of incubation, colonies greater than or equal to 300 µm were enumerated. 
The data is presented as the mean +/- SEM of triplicate dishes of cells in soft 
agarose. C. Melanin production. B16 cells were treated with the indicated 
concentration of RA, phorbol dibutyrate, or a combination of these two agents. In 
the latter case, phorbol dibutyrate was pre-incubated with the cells for 24-h to 
down-regulate PKCα prior to addition of RA. After 48-h of incubation, cells were 
harvested for cell counts and measurement of intracellular melanin as described 
in Methods. Data is presented as the mean +/- SEM of triplicate dishes of cells. 
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These experiments were repeated twice with similar results.   * - comparison 
between PDB with or without RA and control; † - comparison of colony formation 
between PDB+RA and RA alone. (* P<0.01, † P<0.001) 
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Establishment of B16 cells expressing PKCα mutant protein: In light of the 
results described above, together with our previous data showing that retinoic 
acid induces a 6 to 8-fold increase in PKCα mRNA and protein, we formulated 
the hypothesis that PKCα might have non-enzymatic functions in the promotion 
of melanoma cell growth and differentiation. To test this hypothesis, we obtained 
two types of PKCα mutant constructs from Dr. S. Ohno’s laboratory (Yokahama 
City University Medical School, Japan). One construct has a mutation in the ATP-
binding site, which renders the encoded protein catalytically inactive. However, 
since we were concerned about how the conformation of the mutant protein (it is 
unlikely to achieve a mature conformation due to lack of auto-phosphorylation 
activity) might affect its ability to interact with other proteins, we obtained a 
second construct with mutations in the pseudo-substrate region. The PKCα 
encoded by this mutated cDNA would normally be constitutively active, but due 
to the second mutation in the ATP-binding site it is still catalytically inactive. B16 
melanoma clones stably expressing these mutant PKCα proteins were isolated. 
The selection of overexpressed PKCα mutant clones relies on two criteria; first, 
overexpression of PKCα protein and second, low PKC specific enzyme activity 
despite the overexpression of the protein. This occurs because over-expressed 
enzymatically inactive PKCα competes for the binding of PKC substrates by the 
wild-type endogenous enzyme, which results in less phosphorylation of PKC 
substrate.  
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Upon assay, the selected PKCα mutant clones expressed different levels 
of PKCα protein (Fig. 9 insert). Clone KR2 has the highest level of PKCα protein, 
about 7 times that of the control. Clone RE3 also has higher levels of PKCα 
protein, about 5 times that of the control. The PKCα protein levels in clone RE1, 
RE2, and KR1 are three, five, and two times that of the control, respectively. The 
over-expression of dominant-negative PKCα, either the open-conformation or the 
closed-conformation, inhibited the anchorage-dependent and –independent 
growth in the B16 cells. Figure 9 shows the amount of immunoreactive PKCα and 
total PKC enzyme activity in these various clones. Despite this high expression of 
PKCα, these clones have markedly lower PKC enzyme activity than wild-type 
cells. Clones KR1, KR2, RE1, RE2, and RE3 meeting the criteria of high PKCα 
protein expression, but low PKC-specific enzyme activity, were examined for 
their growth and differentiation characteristics. 
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Figure 9. Expression of PKCα protein and enzyme activity in B16 clones 
transfected with plasmids encoding PKCα mutants. B16 cells were 
transfected individually with the plasmids encoding the two different mutant 
PKCα cDNAs. Clones were selected for their ability to grow in G418. One 
hundred clones were selected and then tested for the total amount of PKCα 
protein by Western blotting (insert). These clones were also tested for PKC 
enzyme activity using the Amersham kit as described in Methods. Positive clones 
were identified as those which expressed higher amounts of PKCα protein 
compared to wild type cells and yet had markedly lower PKC enzyme activity 
compared to wild type cells. C − contol with no exogenous PKCα; KR − G418 
resistant clone containing PKCα protein with single mutation in ATP-binding site; 
RE − G418 resistant clone containing PKCα protein with mutation in both the 
pseudo-substrate region and the ATP-binding site. PKC enzyme activity is 
expressed as pmol 32P incorporated into the synthetic PKC substrate 
peptide/min/mg protein. Positive clones were identified as those which expressed 
higher amounts of PKCα protein compared to wild type cells and yet had 
markedly lower PKC enzyme activity compared to wild type cells. 
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Figure 9 
 
 
 
 
 
 
 
 
 63
  
Anchorage-dependent growth in PKCα mutant clones: We found that cells 
expressing the mutant PKCα had slower rates of growth than untreated wild-type 
B16 cells, there were 36 - 66% decreases in cell numbers at 72-h compared to 
the wild-type control (Fig. 10). As a comparison, we treated wild-type cells with 
retinoic acid and observed the expected inhibition of proliferation. The growth 
rate of retinoic acid-treated cells was similar to the untreated PKCα mutant 
clones. In general there was a direct correlation between the growth rate and 
PKC enzyme activity, i.e. low enzyme activity = slow rate of growth, and an 
inverse correlation between growth rate and PKCα protein level. This suggests a 
direct correlation between the level of inactive PKC protein and growth inhibition. 
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Figure 10. Anchorage-dependent growth in B16 clones expressing mutated 
PKCα proteins. Wild-type B16 cells and clones expressing functionally inactive 
mutated PKCα proteins were seeded in 60 mm dishes at 2.8 × 105/dish. 
Triplicate dishes of cells were harvested every 24h for a total of 72h. Cell number 
was measured by use of a hemacytometer. For comparison to the growth rate of 
the clone, wild-type cells were also treated with 10 µM RA and growth measured 
as described above. The data is presented as the mean +/- SEM of triplicate 
dishes. The entire experiment was repeated three additional times with similar 
results. WT-C − wild-type B16 cells treated with DMSO; WT-RA − wild-type B16 
cells treated with RA; KR-1, KR-2 − clones expressing PKCα with mutation in the 
ATP-binding site; RE1-3 − clones expressing PKCα with mutations in both the 
ATP-binding site and the pseudo-substrate region. (* P<0.01) 
A. Growth curves of PKCα mutant clones with single mutation.  
B. Growth curves of PKCα mutant clones with multiple mutations.
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Anchorage-independent growth in PKCα mutant clones: B16 cells, like most 
invasive tumor cells, have the ability to grow in an anchorage-independent 
fashion. This is most conventionally measured by the number of spherical tumor 
colonies formed in soft agarose. This particular phenotype is very sensitive to 
inhibition by retinoic acid. As can be seen in Figure 11A, except for clone RE1, 
there was a direct correlation between the number of soft agarose colonies in the 
PKCα mutant clones vs. wild type cells and their PKC enzyme activity (Fig. 9). In 
contrast, there was an inverse correlation between the number of soft agarose 
colonies in the PKCα mutant clones vs. wild-type cells and the relative amount of 
PKCα protein (Fig. 11). The clone RE1 was retested and found to have lost the 
expression of the mutant PKCα, i.e., its PKC enzyme activity was similar to wild-
type cells (Fig. 11B).  Therefore, the PKC enzyme activity of these clones was 
measure periodically to make sure that all the PKCα mutant clones used in the 
following experiments had lower enzyme activity compared to that in the wild-
type B16 cells. 
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Figure 11.  Anchorage-independent growth in B16 clones expressing 
mutated PKCα proteins. A. Colony formation in soft agarose. Wild-type B16 
cells and clones previously shown to have functional PKCα mutant proteins were 
seeded at 5,000 cells/dish in growth medium containing 0.3% agarose over a 
base of growth medium containing 1% agarose. The semi-solid phase containing 
the cells was overlaid with growth medium, which was replenished every two 
days. At the end of 10 days of incubation, the colonies greater than 300 µm were 
counted. The data are presented as the mean +/- SEM of triplicate dishes. This 
experiment was repeated twice with similar results. B. Re-evaluation of PKC 
enzyme activity. Due to the unexpected number of colonies formed by clone RE1, 
all the clones and wild-type cells used in A were re-assayed for PKC enzyme 
activity using the assay kit from Amersham as described in Methods. The relative 
PKC specific enzyme activity of wild-type cells is set as 1.0. Notice that there is a 
good correlation between relative PKC enzyme activity and the ability to form 
colonies in soft agarose.  
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Melanin production in PKCα mutant clones: Retinoic acid treatment of B16 
melanoma cells induces a 2-3 fold increase in melanin production. Ectopic 
overexpression of PKCα also results in a higher amount of melanin production 
(Gruber et al., 1992). However, as can be seen in Figure 12, none of the clones 
which expressed mutant versions of PKCα lacking PKC enzyme activity had 
higher melanin content than wild-type cells. Three out of four times the medium 
melanin produced by clone RE1 was not significantly different from the wild-type 
B16 cells. Also treatment of these clones with retinoic acid failed to increase 
melanin production, except for KR2, in which retinoic acid increased the amount 
of melanin found in the growth medium. These data suggest that PKCα enzyme 
activity is involved in RA induced increase of melanin production in B16 cells. 
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Figure 12. Melanin production in control and retinoic acid treated wild-type 
and PKCα mutant protein expression clones. Wild-type B16 cells and clones 
expressing the different mutated PKCα proteins were treated with +/- 10 µM RA 
for 48 h. After this incubation, cells were harvested for cell counts and 
measurement of intracellular and extracellular melanin as described in Methods. 
Data is presented as the mean +/- SEM of triplicate dishes of cells. The entire 
experiment was repeated three additional times with similar results. KR-1, KR-2 − 
clones expressing PKCα with mutation in the ATP-binding site; RE1-3 − clones 
expressing PKCα with mutations in both the ATP-binding site and the pseudo-
substrate region. (* P<0.05) 
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AP-1 transcriptional activity in PKCα mutant clones: Treatment of wild-type 
B16 cells with retinoic acid results in an increase in AP-1 transcriptional activity 
(Desai and Niles, 1997). This increase occurs in a slow fashion, but is maintained 
for the duration of the treatment period. Recent evidence suggests that this AP-1 
activity appears to be required for retinoic acid’s effect on B16 growth arrest and 
differentiation (Huang and Niles, 2002). All of the PKCα mutant clones had 2 to 6 
-fold increase on AP-1 transcriptional activity as in wild-type B16 cells (Fig. 13). 
RA treatment did not significantly increase AP-1 transcriptional activity in the 
clones.  
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Figure 13. AP-1 transcriptional activity in control and retinoic acid-treated 
wild-type and clones expressing mutated PKCα. Wild-type B16 cells and 
clones expressing the different mutated PKCα proteins were transfected with an 
AP-1-luciferase reporter gene plasmid, together with a gene encoding β-
galactosidase to correct the transfection efficiency, as described in Methods. 
Transfected cells were treated with +/- 10 µM RA for 24 h, after which they were 
harvested and assayed for luciferase and β-galactosidase activity. The data are 
presented as the mean +/- SEM relative luciferase activity, corrected for β-
galactosidase activity, from triplicate plates of transfected cells.  The PKC 
enzyme activities of all these clones were checked to be much lower than that of 
the wild-type B16 cells. This experiment has been repeated for two additional 
times with similar results. (* P<0.05) 
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Effect of overexpression of mutated PKCα on other PKC isozymes in B16 
cells: One possible reason for the phenotype seen in clones expressing the 
mutant PKCα could be an alteration in the level of activation of other PKC 
isozymes. It appears that PDK-1 (Sonnenberg et al., 2001) is required to 
phosphorylate most PKC isozymes on the activation loop as the first step in their 
maturation. Overexpression of PKCα could potentially sequester the PDK and 
prevent it from activating the other PKC isozymes. To examine this possibility, we 
measured the amount of total and phosphorylated PKC isozyme, an indicator of 
its state of activation (where the two sets of antibodies were available) in wild-
type and clones expressing the PKCα mutants. Figure 14 shows that level of total 
and phosphorylated PKCδ and ζ was similar in wild-type B16 cells and in clones 
expressing either of the two PKCα mutant proteins. Therefore overexpression of 
PKCα did not inhibit the phopshorylation of other PKC isozymes. 
 
 
 
 
 
 
 
 
 
 78
  
Figure 14. Phosphorylation of PKC isozymes in wild-type cells and clones 
expressing mutated PKCα. The amount of total and phosphorylated PKCδ 
(phospho ser642) and PKCζ/λ (phospho thr403/410) in wild-type B16 cells and 
clones expressing mutated PKCα was determined by Western blotting. The 
antibody to phospho PKCζ also recognizes PKCλ. The experiment was repeated 
twice with similar results. 
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Discussion 
 
Retinoic acid is an effective inducer of B16 melanoma growth arrest and 
differentiation. We have previously shown that treatment of these cells with 
retinoic acid increases the expression of PKCα mRNA and protein (Niles and 
Loewy, 1989; Rosenbaum and Niles, 1992) and ectopic expression of PKCα 
mimics the phenotype induced by retinoic acid (Gruber, et al., 1992). Interestingly, 
treatment of PKCα-overexpressing cells with phorbol ester, such as phorbol 
dibutyrate, was not required for the observed phenotype. The comparison 
between the highly metastatic B16 mouse melanoma cells and the weakly 
metastatic amelanotic B78-H1 melanoma cells by La Porta CAM group (La Porta 
and Comolli, 1997) showed that the activity of PKCα is higher in B16 cells than in 
B78-H1, without changes in the PKCα expression. Previous studies in this 
laboratory showed that retinoic acid treatment enriches the subcellular 
distribution of PKCα in the nucleus. Retinoic acid treatment increased the amount 
of PKCα associated with nuclei by approximately 15-fold, while phorbol 12-
myristate-13-acetate (PMA) treatment did not alter the amount of PKCα 
associated with the nuclear fraction, and the retinoic acid-induced increase of 
nuclear PKCα was much greater than that for total PKCα (Gruber et al., 1995). 
These results together with some of our other studies (Gruber, et al., 1995; Niles, 
et al., 1996), led us to examine whether PKCα enzyme activity is required to 
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exert its role in the pathway by which retinoic acid induces melanoma 
differentiation. 
Staurosporine, has been used as a PKC inhibitor in a number of studies, 
is very potent in inhibiting PKC enzyme activity but is not selective for PKC. In 
contrast bisindolylmaleimide, also termed Go6850 or GF 109203X, is a very 
selective and yet potent inhibitor for PKC (Toullec et al., 1991). 
Bisindolylmaleimide inhibited most PKC isozymes, but with a ranked potency of 
alpha > beta > epsilon > delta > zeta (Martiny-Baron et al., 1993). The half- 
maximal inhibitory concentration (IC50) was in the nanomolar range (8 nM) for 
PKCα, while the IC50 for PKCε was 15 times higher (132 nM). Since B16 cells do 
not express PKCβ and γ, bisindolylmaleimide can be used as a relative specific 
inhibitor for PKCα. Based on the results presented in this study we conclude that 
increased PKCα enzyme activity is not required for retinoic acid action since the 
selective inhibitor bisindolylmaleimide did not reverse the effect of retinoic acid 
on inhibition of anchorage-dependent and –independent growth or induction of 
melanin production. Indeed, the PKC enzyme inhibitor, when added to the cells 
in the absence of retinoic acid, mimicked the phenotype induced by this retinoid. 
These results are consistent with various reports (Arita et al., 1992; Baltuch et al., 
1995; Florin-Christensen et al., 1996) demonstrating that PKCα enzyme activity 
is associated with increased growth in several different cell types. Combining 
bisindolylmaleimide and retinoic acid further inhibited the growth and induced 
melanin production to a greater extent than either bisindolylmaleimide or RA 
alone. Since activation of PKCα enhances its degradation process, inhibition of 
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the PKCα enzyme activity by bisindolylmaleimide may prolong the half life of 
PKCα. This may be the reason that bisindolylmaleimide inhibits the proliferation 
of B16 and enhances the action of retinoic acid. 
The issue of PKCα enzyme activity in retinoic acid-treated cells was 
further examined using a newly available phospho-specific antibody that 
recognizes phospho-thr638 in PKCα. Since this site is regulated by 
autophosphorylation, it is one measure of in vivo enzyme activity. Our data show 
that while retinoic acid induces an 11-fold increase in total PKCα protein, there is 
only a two-fold increase in PKCα autophosphorylation, which is in agreement 
with the RA-induced increase in phosphorylation of the PKC substrate MARCKS 
protein (Gruber, et al., 1995). These data, together with the PKC inhibitor results, 
support the conclusion that PKCα enzyme activity is not a crucial component of 
the retinoic acid signaling pathway. 
Phorbol esters are the most powerful and widely recognized tumor 
promoters.  The application of nanomolar concentrations of PMA causes > 99% 
of initiating mice to develop papillomas, with an average of 14 tumors per 
survivor (Yamasaki et al., 1981). Phorbol esters bind to and activate PKC. During 
normal signaling processes, PKC is transiently activated by DAG. PMA is a 
stronger PKC activator than DAG and, in contrast to DAG, is not rapidly 
metabolized by the cell. Investigators (Lu et al., 1998) have shown that the 
activation of PKCα, δ, and ε by phorbol esters or diacylglycerol stimulated the 
ubiquitination and subsequent proteosomal degradation of these PKC isoforms. 
The ubiquitination and degradation appeared as early as 30 minutes after 12-O-
 83
  
tetradecanoylphorbol-13-acetate (TPA) treatment, while enzymatically inactive 
mutant PKCα was protected from the degradation stimulated by TPA. 
Proteosome inhibitors were able to block this PKC degradation and also the 
TPA-induced transfomation of cells. The PKCα protein level in B16 cells was 
dramatically decreased by a 2-h application of PDB (data not shown). Long term 
treatment of B16 cells abolished levels of PKCα but not atypical PKCλ protein 
which does not respond to PDB activation (data not shown). Instead, PDB 
increased the PKCλ protein level as early as 24-h of treatment. The increase of 
PKCλ induced by PDB might be a result of compensation for cPKCs and nPKCs 
lost by long term PDB treatment. Treatment of B16 cells with PDB increased their 
anchorage-dependent growth rate, increased their ability to form colonies in soft 
agarose, and reduced melanin production. If PKCα protein is required for RA-
induced differentiation, long term treatment of PDB should reverse the action of 
RA. Indeed, our study showed that PDB reversed RA’s effect on inhibiting 
anchorage-dependent and -independent growth and stimulating melanin 
production (Fig. 8 A-C).  
 We investigated the effect of decreasing PKCα protein level by taking 
advantage of the ability of extended phorbol dibutyrate treatment (24-48 h) to 
deplete cells of PKC protein. We initially attempted a more specific anti-sense 
PKCα method (Dean, et al. 1996) to achieve this objective. But we were not 
successful in obtaining significant reduction in the level of PKCα protein using 
either transient or stable expression of the antisense oligonucleotide. The data 
published by Zhao et al. (2001) using antisense PKCα in B16 cells showed that 
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antisense PKCα inhibited the mannosylerythritol lipid-induced melanin production 
in B16 cells, no other phenotype change was reported by this group. In B16 cells, 
when PKC was down-regulated, we obtained results opposite to those with PKC 
enzyme inhibitors, i.e., the activity of retinoic acid was antagonized. Short term 
treatment of cells (2 h) with phorbol dibutyrate prior to the addition of retinoic acid 
did not antagonize the activity of this retinoid (data not shown). Brooks et al. 
(1993) have previously shown that the growth of melanocytic cells is associated 
with down-regulation of PKCα and thus provides an explanation for the 
antagonism of retinoic acid induction of growth arrest and differentiation. 
Our data suggest that retinoic acid induction of PKCα protein, but not its 
enzymatic activity, is important in the signaling pathway leading to growth arrest 
and differentiation. However, long term treatment of PDB reduces the protein 
levels of all cPKCs and nPKCs, and phorbol esters have other functions. 
Because of the relative selectivity of bisindolylmaleimide to PKCα at low 
concentrations in vitro, it is hard to monitor its in vivo concentration. More direct 
evidence is needed to prove that PKCα protein, but not enzyme activity, has a 
role in RA induced B16 cell growth arrest and differentiation. There are no 
isozyme-specific PKC enzyme inhibitors available. However, there are several 
other approaches one can employ to examine the specific role of PKCα, i.e., 
over-expression of PKCα and down-regulation of PKCα by either dominant-
negative PKCα or antisense oligonucleotide of PKCα. This laboratory has used 
the approach of over-expression of wild-type PKCα, and showed that over-
expression of PKCα mimicked the effect of RA treatment on B16 melanoma cells.  
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In order to further investigate the possible non-enzymatic role of PKCα, we 
used plasmids encoding two different mutant forms of PKCα. Both of these 
plasmids encode enzymatically inactive PKCα, however, one plasmid has 
additional mutations in the pseudo-substrate region which should result in a 
PKCα protein in the catalytically competent conformation. Clones of B16 cells 
expressing either of these mutant PKCα proteins had some, but not all of the 
phenotypes found in retinoic acid-treated cells, i.e., these clones had a 
decreased growth rate, decreased colony formation in soft agarose and 
increased AP-1 transcriptional activity compared to either wild-type cells or 
clones that did not express the mutant PKCα proteins. However, clones 
expressing the mutant PKCα proteins did not have increased melanin production 
relative to wild-type cells.  
The numbers of colonies formed by B16 clones expressing mutant PKCα 
was greatly decreased compared to the wild type cells; there were very few 
colonies detectable in clones KR2 and RE3. The number of colonies formed 
seemed to correlate with the total PKCα protein level, or inversely correlated with 
the enzyme activity of each clone. Of note, in Figure 11A,  a late passage of 
clone RE1 had about the same number of colonies as the wild-type B16 cells in 
soft agarose, while previous experiments showed that RE1 had a lower number 
of colonies compared to the wild-type B16 cells. The cause of this change was 
the loss of mutant PKCα through passage, which resulted in the restoration of the 
enzyme activity of this clone (shown in Figure 11B). This finding provides indirect 
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evidence that a non-enzymatic effect of PKCα protein is responsible for the 
inhibition of melanoma B16 cell colony formation in soft agarose. 
This inhibition of monolayer growth or colony formation correlated with the 
PKCα protein level of these clones (Fig. 9). For example, KR2 and RE3 had the 
slowest rate of growth and formed very few colonies in soft agarose; the KR2 and 
RE3 clones had higher amounts of PKCα protein than other clones.  
Melanin production is cell density-dependent. After B16 cells reach a 
critical cell density, melanin production is rapidly increased. The clones 
expressing mutant PKCα have different growth rates, and therefore it was difficult 
to arrive at the same cell densities among different clones and wild type B16 cells. 
The densities of the clones expressing mutant PKCα in Figure 12 were much 
greater than the wild-type B16. Even though they were more confluent, the 
amount of melanin produced per cell number of the clones expressing mutant 
PKCα was not higher than the wild-type B16 cells. Furthermore, RA treatment did 
not stimulate melanin production in these clones, as it did for the wild-type B16 
cells. These data may indicate that PKCα enzyme activity is required for melanin 
production. 
Melanin production is a marker of differentiation of B16 cells. The enzyme 
that is very important in controlling melanogenesis is tyrosinase. Melanin content 
has shown to be correlated with tyrosinase activity but not with protein level 
(Iozumi et al., 1993). Alpha-MSH (melanocyte stimulating hormone) stimulates 
PKC activity in B16 cells (Buffey et al., 1992), and α-MSH-induced pigmentation 
was blocked by depletion of PKC (Park et al., 1996). Long term PDB treatment 
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depleted PKCα, which resulted in decreased melanin production (data not 
shown).  
Increased AP-1 activity is associated with survival and proliferation and is 
decreased by retinoic acid in many cell lines. However in B16 cells long term 
treatment with retinoic acid increases AP-1 activity, and overexpression of 
dominant-negative c-fos, a component of the AP-1 complex, is able to block 
retinoic acid-induced growth inhibition and differentiation (Huang and Niles, 
2001). Moreover, bisindolylmaleimide slightly increased AP-1 activity in B16 cells 
and does not block retinoic-acid induced AP-1 activity (Desai and Niles, 1997). 
AP-1 activity is increased in clones with overexpression of mutant PKCα, and 
further increased with retinoic acid treatment. These data indicate that retinoic 
acid-induced AP-1 activity does not require PKCα enzyme activity. 
It appears that the conformation of PKC does not affect the growth rate of 
these mutant-expressing clones. Clones expressing mutant PKCα eithr in the 
open-conformation or closed-conformation grow slower that wild-type B16 in 
monolayer and soft-agarose. There were also no apparent phenotypic 
differences between clones expressing these two different mutant PKCα proteins. 
There are several possibilities to explain these results. First, PKCα protein 
which is induced by retinoic acid could have non-enzymatic functions. It has been 
reported that PKC stimulates phospholipase D activity through a non-enzymatic 
mechanism (Singer et al., 1996). Also PKC binds to proteins other than 
substrates (Diaz-Meco et al., 1996; Mochly-Rosen, 1995). The phenotypes of 
clones with overexpression of wild-type PKCα are similar to the phenotypes of 
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clones with overexpression of mutant PKCα in regards to anchorage–dependent 
or –independent growth, but not for melanin production. The major difference 
between these two types of clones is that the PKCα mutant clones lack enzyme 
activity. It may indicate that while PKCα enzyme activity is not necessary for RA-
induced inhibition of growth, RA-induced melanin production requires PKCα 
enzyme activity.  
A second possibility is that the PKCα mutants, acting as dominant-
negative proteins, could interfere with the maturation or activity of other PKC 
isozymes via sequestering PDK or substrate respectively. This could lead to a 
phenotype similar to wild-type B16 cells treated with the PKC-selective enzyme 
inhibitor bisindolylmaleimide (Fig. 6 A-C). However, using phospho-specific 
antibodies, we found that PKCδ, ζ, and λ maturation was not changed as a 
function of the expression of the mutant PKCα proteins in the various clones. 
Overexpression of PKCα does not alter the immunoreactive protein levels of 
other PKC isoforms (δ, ε, η, ζ, µ), similar to findings by several other investigators 
(Jansen et al., 2001; Zhao et al., 2001).  Also inhibition of PKC enzyme activity 
with bisindolylmaleimide led to an increase in melanin production, while 
expression of the mutant PKCα proteins did not increase melanin production. 
Thus it is uncertain how PKC may be involved in the pathway by which retinoic 
acid stimulates melanin synthesis. Despite this uncertainty, it is clear that the 
increased PKCα in retinoic acid-treated cells does not require catalytic activity to 
mediate effects on melanoma cell growth and differentiation.  
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Our data indicate that PKCα enzyme activity is not required for its 
inhibitory effects on growth of B16 cells. Further investigation is needed to 
determine whether the kinase activity of PKCα functions as a tumor promoter. 
Enzymatically active PKCα activates the MAPK pathway, which is responsible for 
cell motility, invasion of tumor cells, melanin production and other physiological 
responses (Cartwright et al., 2002; Kim et al., 2002; Kim et al., 2003). Short term 
PDB treatment (2 h) increases phosphorylated MAP kinases, Erk1/2 and p38, 
without a change in their total protein level in B16 cells. 
It is possible that the functions of PKCα as a protein and as a kinase are 
separated. For example, stimulation of melanin production may be a function of 
kinase activity, while suppression of growth may be a function of the protein itself. 
Our data support this hypothesis. Sun and Rotenberg (1999) reported that 
overexpression of PKCα suppresses proliferation, while increased expression of 
PKCα catalytic activity in MCF-10 breast cancer cells increased their metastatic 
potential (Sun et al., 1999). These two separate properties might compete with 
each other, since activation of PKCα enhances its degradation and results in a 
decrease in the level of the protein, and an increased level of enzymatically 
immature PKCα protein will compete with activated PKCα for substrates. Our 
data suggest that the non-enzymatic function of PKCα mediates retinoic acid-
induced growth arrest, while PKCα enzymatic activity mediates phorbol ester-
induced tumorigenesis. 
There are many studies and clinical trials which have used PKC enzyme 
inhibitors or PKCα antisense oligonucleotide as anti-tumor drugs (Cotter, 1999; 
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Yuen et al., 2000). Given the fact that activated PKCs (conventional and novel) 
are subjected to ubiquitination and subsequent degradation, the data in this 
research are not necessarily in contradiction to the studies that activated PKCα is 
involved in carcinogenesis induced by phorbol esters. When the selective PKC 
inhibitor bisindolylmaleimide was used, similar effects seen with RA-treated B16 
cells was obtained, i.e., inhibition of anchorage-dependent, -independent growth 
and increased melanin production. Using PKCα antisense oligonucleotides to 
treat cancers over-expressing PKCα is a valid approach. However if it is used to 
specifically taget at PKCα activity based on tumor promoting agent TPA and 
phorbol esters increasing PKCα activity, the antisense PKCα oligonucleotide will 
not only inhibit its enzyme activity, but also deplete the PKCα protein, this might 
partially explain the mixed results from these studies.  
We hypothesize that PKCα interacts with other proteins such as 
coactivators. We found by immunoprecipitation a 30 KDa protein which was 
associated with PKCα. The amount of this protein was much greater in retinoic 
acid-treated B16 cells compared to control. The identity of this protein needs to 
be further investigated. One future approach is to explore the identity of PKCα 
binding proteins in control vs. retinoic acid-treated B16 cells using the yeast two-
hybrid system. 
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Chapter ΙΙ 
 
 
The Role of PKCλ and Cell Cycle 
Regulators in Retinoic Acid Induced 
Growth Arrest and Differentiation
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Introduction 
 
PKC isozymes have diversified functions in relation to cell growth and 
other biological functions. I have found that there are seven PKC isozymes 
expressed in B16 melanoma cells. PKCα is the only PKC isozyme whose level is 
increased by retinoic acid treatment. The levels of PKCλ and PKCµ are 
decreased about 50% by 48h retinoic acid treatment. Interestingly, we found that 
the amount of PKCλ protein varies with the cell growth rate, i.e., its level 
increases with rapid proliferation and decreases with a slower growth rate. 
PKCλ/ι and PKCζ are the only two known members of the atypical PKC family. In 
contrast to other PKC isoforms, the atypical PKCs can not be activated by 
calcium, phorbol esters or diacylglycerol. While the classic and novel PKC 
isoforms have been extensively studied, little is known about expression, 
regulation, and functions of the atypical PKCs. PKCλ/ι has been implicated in the 
control of important cellular functions like cell proliferation, survival, glucose 
transport, and establishment of cell polarity. Down-regulation of PKCλ/ι with 
antisense oligonucleotides or transfection of a kinase-inactive dominant-negative 
mutant severely impairs cell proliferation (Berra et al., 1993) and MAPK 
activation (Berra et al., 1995). Various studies have found that PKCλ/ι is involved 
in embryogenesis, and its expression decreases in differentiated cells.  It has 
been reported that the induction of cyclin D1 by oncogenic Ha-Ras requires 
PKCλ (Kampfer et al., 2001).  However, the function and mechanism of PKCλ is 
not well studied, and there is no report on the expression and function of PKCλ in 
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melanoma. The link between PKCλ expression and the rate of B16 cell growth 
led us to investigate the role of PKCλ in B16 mouse melanoma cell proliferation 
by overexpression of PKCλ. We also investigated the changes in cell cycle 
regulatory proteins in clones over/under-expressing PKCλ and in B16 cells 
treated with retinoic acid. 
The cell cycle is divided into several phases, the quiescent phase (G0), 
the DNA synthesis phase (S), the mitosis phase (M), and before S phase and 
after M phase, there are two gap phases, named G1 and G2, respectively. There 
are several check points during the cell cycle. The G1 checkpoint is the rate-
limiting step in the cell cycle progression. Once the cell passes the G1 phase, it 
is committed to cell division. The cell cycle is precisely regulated and coordinated. 
The proteins that are involved in the cell cycle regulation are the cyclin family and 
the cyclin-dependent kinases (cdks). The holoenzyme complex contains a 
regulatory subunit, the cyclins, and a catalytic cdk subunit. While the levels of 
cdks remain constant throughout the cell cycle, the expression of cyclins varies 
and they have a periodical pattern during the cell cycle. The major cyclins that 
are involved in cell cycle regulation are A-type cyclin, B-type cyclin, D-type cyclin 
(cyclin D1, D2, and D3), and E-type cyclin (cyclin E1 and E2). The cyclins 
assemble with their catalytic partners and control different stages of the cell cycle. 
During G1, the D-type cyclin appears before cyclin E. The cyclin D associates 
with cdk4 and cdk6 and its amount increases during G1 progression 
(Matsushime et al., 1992; Morgan, 1997). The activation of cyclinD/cdk4 or 6 
complex is the rate-limiting step in the G1-to-S phase transition. The E-type 
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cyclin accumulation happens in late G1 phase. Cyclin E associates with and 
activates cdk2 (Koff et al., 1992). The cyclinE/cdk2 complex is also involved in 
the G1-to-S phase transition. Cyclin A regulates cdk2 and cdc2, and the 
cyclinA/cdk2 complex is essential for S phase progression. Cyclin B associates 
with cdc2 and is involved in mitosis.  
 
Cyclin-dependent kinase inhibitors (CKI’s) block the activity of cyclin/cdk 
complexes and prevent cell cycle progression. There are two major CKI families, 
the Ink4 (inhibitor of cdk4) family and the Cip/Kip (Cdk interacting protein/Kinase 
inhibitory protein) family. P16Ink4a, p15Ink4b, p18Ink4c, and p19Ink4d make up 
the Ink4 family (Serrano et al., 1993; Hannon and Beach, 1994; Guan et al., 1994; 
Hirai et al., 1995). Ink4 proteins compete with D-type cyclins for binding to the 
cdks and thereby inhibit cyclin D-associated kinase activity. Ink4 proteins are 
expressed in a cell-type specific manner. Of note, p16Ink4a is mutated in 
melanoma. Currently, p21Cip1, p27Kip1, and p57Kip2 make up the Cip/Kip 
family (Haper et al., 1993; Gu et al., 1993; Koff et al., 1993; Lee et al., 1995; 
Matsuoka et al., 1995). These proteins interact with cdk2 and cdk4 and inhibit the 
activity of the cyclin/cdk complexes. Cip/Kip proteins preferentially inhibit cdk2 in 
vivo.  
 
Retinoblastoma (Rb) protein is one the substrates of cdks. In the absence 
of mitogen stimulation, Rb binds to E2F and represses its transcriptional function. 
E2Fs are transcription factors that regulate the expression of many genes whose 
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products are necessary for the G1/S transition and S phase (Harbour and Dean, 
2000).  Rb is only able to block the activity of E2F when it is hypophosphorylated. 
Rb is first phosphorylated by the cyclin D/cdk4 complex, which induces the 
interaction between the central domain and the C-terminal part of Rb, allowing 
the cyclin E/cdk2 complex to phosphorylate Ser567, a residue that is normally 
inaccessible (Harbour et al., 1999). The hyperphosphorylated Rb releases E2F, 
which then activates the transcription of genes that are involved in G1/S 
transition and S phase. One of the gene targets of E2F is cyclin E (Geng et al., 
1996). The initial phosphorylation of Rb by cyclin D/cdk4 also disrupts its 
interaction with HDAC, thereby relieving the repression of the cyclin E gene and 
allowing further progression into S (Zhang et al., 2000). Cyclin D/cdk complexes 
also regulate the activity of cyclin E/cdk2 by a second mechanism in that cyclin 
D/cdk4 complexes sequester the Cip/Kip cell cycle inhibitors (Sherr and Roberts, 
1999). The majority of cyclin/cdk complexes interact with p21waf1, which then 
stabilizes the complexes and prolongs their half life. Cyclin D/cdk4 competes with 
the cyclin E/cdk2 for binding of p21, thereby releasing the p21 inhibition of cyclin 
E/cdk2, allowing cells to progress to S phase. Therefore, the main role of cyclin 
D/cdk4 is to activate the cyclin E/cdk2 complex. Knock-in mice in which the cyclin 
D1 locus was replaced by cyclin E exons confirmed that absence of cyclin D 
negates the activation of the cyclin E/cdk2 complexes (Geng et al., 1999). The 
hyperphosphorylation of Rb may be maintained during the S phase by cyclin 
A/cdk2. 
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As mentioned in the Literature Review, retinoic acid induces G1 arrest in 
cells, including cancer cells (Preisler et al., 1992; Mangiarotti et al., 1998). The 
effect of retinoic acid on cell cycle is related to its regulation of the cell cycle 
regulator proteins. The correlation of PKCλ protein with B16 cell growth rate led 
me to investigate the relationship between retinoic acid, PKCλ, and cell cycle 
regulator proteins. 
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Materials and Methods 
 
 
 
    Cell Culture: B16 mouse melanoma cells were cultured in a humidified 
atmosphere of 5% CO2, 95% air at 37°C in Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco, Grand Island, NY). This medium contained 1 g/l glucose and 
was supplemented with 10% bovine calf serum (Hyclone) for most of the 
experiments or 10% fetal bovine serum for growth studies with stably over-
expressing PKCλ. The medium was also supplemented with 50 units/ml penicillin 
G, and 50 µg/ml streptomycin sulfate.  
    Reagents: All the reagents used in this research were obtained from 
Sigma (St. Louis, MO) if not stated otherwise. All-trans-RA was obtained from 
Fluka Chemical Company (New York). All experiments involving the use of RA 
were conducted in yellow light to prevent photo-oxidation of the retinoids and the 
RA in each experiment was freshly made. Retinoic acid, bisindolylmaleimide, and 
phorbol 12, 13 dibutyrate were dissolved in dimethyl sulfoxide (DMSO) and 
handled in yellow light. Transfer buffer was 2.5% (w/v) Tris, 1.44% Glycine, 0.1% 
SDS, and 20% (v/v) methanol. TBS was 20 mM Tris pH 7.6, 0.137 M NaCl, and 
0.1% Tween-20. Electrophoresis running buffer was 1.44% Glycine, 0.3% Tris-
base, 0.1% SDS. LB (Luria-Bertani) medium (1.0% Tryptone, 0.5% Yeast Extract 
and 1.0% NaCl) was dissolved in deionized water, the pH  was adjusted to 7.0 
with NaOH, the solution was autoclaved on liquid cycle for 20 minutes at 15 lb/sq. 
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inch, and ampicillin was added to solution to bring the final concentration to 50 
µg/ml after the broth was cooled to 55°C. For LB agar plates, LB medium was 
prepared as above, and 15 g/L agar was added before autoclaving, and then 
poured into 100 mm plates. When the agar was hardened in the plates, they 
were inverted and stored at 4°C. 
  Cell density measurement by crystal violet assay: Crystal violet 
assay is a colorimetric assay that is based on the uptake of crystal violet by 
attached cells in each plate. Cells were fixed with methanol: acetic acid (3:1) for 
1 hour at room temperature. The fixed cells were washed with 80% methanol and 
stained with 0.5% crystal violet for 1 hour. Excess dye was removed by washing 
the plates with distilled water. Plates were air-dried and the dye was eluted with 
0.7 ml of 10% acetic acid. Aliquots of eluted dye from each plate were transferred 
to 96-well plates and absorbance was measured at 575 nm with a Microplate 
Bio-kinetics Reader.  
     Plasmid DNA isolation: Plasmid DNA was isolated using a Mini-prep 
Kit from Eppendorf (Brinkmann Instruments, New York). The manufacturer’s 
protocol was followed to isolate plasmid DNA. 
Transformation: Five to ten nanogram of plasmid DNA or 2 µl of cloning 
reaction was used for transformation. DNA was introduced into competent E.coli 
cells by heat shock at 42°C for exactly 30 seconds. The competent bacteria were 
purchased from Invitrogen.   
  Stable Transfection of B16 Cells:  We transfected B16 cells with 
pcDNA3.1. The day before the transfection, B16 cells were seeded at 0.8 million 
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per plate. Transfection was accomplished by using Lipofectamine plus reagent 
(Life Technologies). For each 100 mm dish, 4 µg of DNA was diluted in 750 µl of 
serum free DMEM, and 20 µl of Plus Reagent was added to DNA and mixed. 
This mixture was incubated at room temperature for 15 minutes. 30 µl of 
Lipofectamine Reagent was diluted in 750 µl of serum free DMEM, and the 
precomplexed DNA was combined with diluted Lipofectamine Reagent and this 
mixture incubated at room temperature for 15 minutes. Cells on the plates were 
washed with PBS to remove residual medium and then 5 ml of serum free DMEM 
was added. The DNA-Plus-Lipofectamine Reagent complexes were added to the 
plates, which were incubated at 37°C with 5% CO2 for 5 hours. After this 
incubation, the volume of medium of each plate was increased to 10 ml and fetal 
bovine serum was added at a final concentration of 10%.  Neomycin-resistant 
clones were selected in DMEM containing 1.43 µg/ml of the neomycin derivative 
G418 (Gibco). 
    Western Blot Analysis:  Cells were seeded at 2x105 /100 mm dish and 
after attachment (overnight), and they were refed with DMEM containing 10% 
fetal bovine serum with or without 10 µM RA. Following a 48-h incubation, the 
medium was removed, cells were washed with PBS and lysis buffer added (62.5 
mM Tris (pH6.8), 2% w/v sodium dodecyl sulfate (SDS), 10% glycerol, 50 mM 
DTT, 0.1% w/v bromphenol blue, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 50 µg/ml 
aprotinin, 0.5 mM phenylmethylsulfonyl fluoride, and 0.5% tritonX-100).  After 
scraping cell from the dishes, the lysates were sonicated for 10 seconds with a 
sonic disruptor (Tekmar Corp., Cincinnati, OH) at power setting 60. Cell debris 
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was removed by centrifugation at 14,000rpm for 5 minutes. Proteins in the 
supernatant were denatured at 100°C for 2 minutes. Equal volumes of cell 
extracts were loaded into 10% SDS PAGE and the proteins electrophoretically 
separated. The separated proteins were electrically transferred to Hybond-C 
Extra nitrocellulose membrane (Amersham). The membrane was incubated for 1 
hour in blocking buffer (5% nonfat dry milk in Tris-buffered saline containing 0.1% 
Tween (TBST)).  The primary antibody was diluted in blocking buffer. The dilution 
for monoclonal anti-PKCα, and -PKCδ antibodies (Upstate Technology) was 
1:3000. The dilution for monoclonal anti-PKCε, -PKCη -PKCλ, and PKCζ 
antibodies (Transduction Laboratories) was 1:400. The incubation time for these 
antibodies was 3 hours. The dilution for anti-GAPDH antibody was 1:5000, and 
the incubation time was 1 hour. Antibodies for the following proteins were diluted 
1: 1000; Erk1/2, p38, phosphorylated-Erk1/2, phosphorylated-p38, 
phosphorylated-PKCα, phosphorylated-PKCδ, phosphorylated-PKCλ, 
phosphorylated-PKCζ, PKCµ, phosphorylated-PKCµ antibodies, p27Kip1, cyclin 
D3, cdk4, cdk6 (Cell Signaling), and p21Waf1 (Pharmingen, CA). All the 
antibodies from Cell Signaling were polyclonal antibodies and the incubation time 
for these antibodies was overnight. The blot was washed 3 times in TBST 
followed by 1-h incubation with a 1:3000 dilution of goat anti-rabbit horseradish 
peroxidase-conjugated secondary antibody (Amersham) for monoclonal primary 
antibody, or rabbit anti-goat horseradish peroxidase-conjugated secondary 
antibody (Cell Signaling) for polyclonal primary antibody. The membrane was 
washed 3 times in TBST after incubation with secondary antibody. Reactive 
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bands were visualized by the enhanced chemiluminescence method (Amersham). 
All washes and incubations were performed at room temperature. The relative 
intensity of each band was measured by a laser scanning densitometer 
(Molecular Dynamic, CA). 
        Monolayer Growth:  Cells were seeded at a density of 2.8x104 
cells/60mm tissue culture dish (Falcon) in 3.6 ml of DMEM containing 10% fetal 
bovine serum. The medium was changed at the second day and 10 µM RA or 
vehicle was added at the same time. Cells were incubated at 37ºC in 7% CO2, 
93% air. At 24-h intervals, cells were harvested by trypsinization, and cells were 
counted with a hemacytometer. 
    Colony Formation in Soft Agarose:  A 3 ml bottom layer of freshly 
prepared 1% agarose/DMEM/10% fetal bovine serum containing the appropriate 
RA concentrations was dispensed into 60mm dishes and allowed to solidify. The 
top layer consisted of 5000 cells suspended in 3 ml of 0.3% agarose/DMEM/10% 
fetal bovine serum containing the respective RA concentrations. Following 
solidification of the top layer, a 2 ml DMEM/10% serum liquid overlay, containing 
the appropriate RA concentrations, was added to each dish. For experiments 
using PDB, B16 cells were grown at monolayer pre-treated with PDB for 24 
hours and then transferred to top layer. The liquid phase was changed every 48 
h. Viable colonies were counted 10 days after seeding. Only colonies greater 
than or equal to 300 µm in diameter were counted. 
Relative Melanin Content of Media and Cells:  Cells were seeded 
into 60 mm dishes so that after 4 days their densities would be similar. After 
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attachment, cells were refed with or without 10 µM RA in DMEM. Exactly 3.6 ml 
medium was added to each dish. Fourty-eight hours after treatment, 1.5 ml 
aliquots of medium were taken from each dish and centrifuged at 12,000 × g for 
10 sec. The relative melanin contents of supernatants were determined by 
measuring the OD462. 800 µl of 1 N KOH were added to each dish. Cell lysates 
were collected and incubated at 80°C for 1 h. The hydrolysates were centrifuged 
at 12,000 x g for 10 sec. The relative melanin concentrations of the supernatants 
were determined by measuring the absorbance at 462 nm. 
Cloning of PKCλ 
 
Isolation of total RNA: Total RNA was isolated from B16 cells using 1 
ml of the TRI REAGENT™ per 10cm dish. The mixture was passed several times 
through a pipette to form a homogenous lysate. The homogenate was 
centrifuged at 12,000 x g for 10 minutes at 4°C to remove the insoluble material. 
The homogenate was incubated for 5 minutes at room temperature to ensure 
complete dissociation of nucleoprotein complexes. Two hundred-microliter of 
chloroform was added to the sample. The mixture was shaken vigorously for 15 
seconds, and incubated for 2-15 minutes at room temperature. The mixture was 
centrifuged at 12,000 x g for 15 minutes at 4°C. Centrifugation separated the 
mixture into 3 phases: a red organic phase (containing protein), an interphase 
(containing DNA), and a colorless upper aqueous phase (containing RNA). The 
upper aqueous phase was transferred to a fresh tube, 0.5 ml of isopropanol was 
added, and this mixture shaken, incubated for 5-10 minutes at room temperature 
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and then centrifuged at 12,000 x g for 10 minutes at 4°C. The total RNA 
precipitate formed a pellet on the side and bottom of the tube. The supernatant 
was removed and the RNA pellet was washed with 1 ml of 75% ethanol. Total 
RNA was stored in ethanol at -70°C. RNA samples were centrifuged for 10 
minutes at 4°C before use. Ethanol was removed and the total RNA sample was 
dissolved in 50 µl of TE buffer (pH 6.8) by pipetting up and down. The total RNA 
solution was vortexed for 1 minute and incubated for 10 minutes in a 60ºC water 
bath. The total RNA solution was then vortexed for 1 minute and centrifuged 
briefly. The concentration of total RNA was determined by the absorbance at 
260/280 nm. Reverse transcription was performed using the Advantage® RT-for-
PCR Kit (Clontech Laboratories, CA). 1 µg of total RNA was added to DEPC-
treated water to a total volume of 12.5 µl. The RNA was heated at 70°C for 2 
minutes, and then quenched rapidly on ice. 4.0 µl of 5x reaction buffer, 1.0 µl of 
dNTP mix, 0.5 µl of Recombinant RNase inhibitor, and 1.0 µl of MMLV reverse 
transcriptase (all these were provided by the kit) were added to the RNA solution,  
mixed by pipetting up and down, and incubated for 1 hour at 42°C. The reaction 
mixtures were heated for 5 minutes at 94ºC to stop the cDNA synthesis and to 
destroy any DNase activity. The reaction mixture was diluted to a final volume of 
100 µl by adding 80 µl of DEPC-treated water, and then vortexed and centrifuged 
briefly. The cDNA was stored at -70ºC.  
Polymerase chain reaction (PCR): Primers to amplify murine PKCλ 
were designed by the DNA Core Facility at Marshall University. The upstream 
primer was 5’ACC ATG TCC CAC ACG GTC G 3’, and the down stream primer 
 104
  
was 5’CTC TTC TGC AGA CAT CAA G 3’. The primers were designed so that 
the cloned gene would be in frame with the sequence from the pcDNA3.1/V5-
His© TOPO® TA Expression vector used in this cloning, such that the V5 epitope 
would be transcribed along with the PKCλ gene. The synthesized primers were 
dissolved in TE buffer (pH 8.0) at a concentration of 40 µM. The following 
components were placed in a 0.5 ml PCR reaction tube: 25 µl of sterile water, 5 
µl of 10xPCR buffer, 1.5 µl of up-stream primer, 1.5 µl of down stream primer, 1 
µl of dNTP mix, 15 µl of cDNA, and 1 µl of Ampli Taq®DNA polymerase. Sterile 
water was added so that the final volume was 50 µl. The thermal cycling 
parameters were 94°C for 30 seconds, 57°C for 30 seconds, and 72°C for 3 
minutes for 25 cycles, and the final extension phase was 10 minutes at 72°C. 
The PCR product was checked by agarose gel electrophoresis, and a single 
band between the predicted size of 1,645 bp and 2,000 bp was detected. 2 µl of 
fresh PCR product was cloned into the TOPO® vector and then transformed into 
chemically competent E.coli following the protocol from Invitrogen Life 
Technologies (Carlsbad, CA). Six colonies were picked and cultured in LB 
medium. Plasmid DNA was isolated using the Perfectprep Plasmid Mini kit from 
Eppendorf AG (Hamburg, Germany). Plasmid DNA was digested by two 
separate restriction enzymes BglII and MscI. The reaction product was checked 
by agarose gel electrophoresis. Two positive clones with PKCλ in the sense 
orientation were selected according to the agarose gel electrophoresis result. 
Plasmid DNA was kept at 4°C for temporary use and -20°C for long term storage. 
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Sequencing: The cloned PKCλ gene was sequenced at the DNA Core 
Facility of Marshall University. DNA sequencing confirmed that the cloned 
sequence was identical to the PKCλ gene sequence from the Gene Bank using 
multiple alignments. 
Agarose gel electrophoresis: Agarose (0.7%) was dissolved in TAE 
(tris-acetic acid-EDTA) buffer by boiling. At about 50ºC, ethidium bromide was 
added to reach a final concentration of 0.5 µg/ml.  
Stable Transfection and Screening: The cloned PKCλ plasmid was 
transfected into wild type B16 cells as previously described in part I and G418 
resistant clones selected and transferred to 30 mm dishes. Once the cells were 
confluent, they were transferred to larger dishes. Western blotting was used to 
screen the clones for over-expression of PKCλ. Anti-V5 (Invitrogen Life 
Technology) antibody was used to detect the PKCλ/V5 epitope fusion proteins. 
For detecting the total PKCλ protein level, anti-PKCλ antibody (Transduction 
Laboratory, Lexington, KY) was used.  
Statistical analysis: Statistical analyses were performed using one way 
ANOVA in SigmaStat™ statistical software (Jandel Scientific; San Rafael, CA). 
Statistical significance was judged at the p<0.05 level. 
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Results
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Expression of PKC isozymes in B16 cells: Of the eleven members of the PKC 
family, there are seven which are expressed in B16 cells. The PKC isozymes 
expressed in B16 cells are PKCα, PKCδ, PKCε, PKCθ, PKCζ, PKCλ and PKCµ 
(Fig. 15). Of these seven PKC isozymes, the only members whose expression 
was altered by retinoic acid treatment were PKCα, PKCλ and PKCµ. PKCα is the 
only isozyme that is increased by retinoic acid treatment. The expression of 
PKCλ and PKCµ was decreased about 50% by a 48-h retinoic acid treatment. 
Since PKCµ is considered by some investigators not to be a member of the PKC 
family due to its disparate catalytic sequence, and since we have previously 
discussed the role of PKCα in retinoic acid induced B16 cell growth inhibition and 
differentiation, the following part of this dissertation will focus on the role of PKCλ 
in B16 cell growth and differentiation. 
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Figure 15. Expression of PKC isozymes in wild-type B16 cells. B16 cells 
were treated with 10 µM RA for 48h and prepared for Western Blotting as 
described in Methods. Replicate blots were incubated with antibodies against 
total PKCα, δ, ε, ζ, θ, λ and µ proteins. The bottom half of each blot was 
incubated separately with antibody against GAPDH to correct for protein loading 
and specificity for RA-induced changes. Following development of the signals by 
chemiluminesence, the relative amount of PKC isozymes was determined by 
densitometry, with correction for the relative amount of GAPDH in each sample. 
A. PKC isozymes whose expression is altered by RA. They are PKCα, PKCλ,  
and PKCµ. B. PKC isozymes whose expression is not changed by RA. They are 
PKCδ, PKCε, PKCζ, and PKCθ. The experiment was repeated twice with similar 
results. 
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Temporal expression of PKCλ in B16 cells: We studied the expression level of 
PKCλ in B16 cells at 24 h, 48 h, 72 h, and 96 h time points treated with or without 
retinoic acid after cells were refed with fresh medium (Fig. 16A). In the absence 
of retinoic acid, PKCλ protein levels increased with time and peaked at 48h, then 
declined at 72 h and reached the lowest point at 96 h (Fig. 16B). Interestingly, 
this temporal variation of PKCλ expression correlates with the B16 cell growth 
rate. Figure 16C is a semi-logarithmic plot of cell density vs. time. With the 
seeding density of 2.8 × 105/60mm culture dish, B16 cells have the highest rate 
of proliferation from 24 to 48 h, after which growth slows, and at the 96 h, they 
reach confluence. These results led us to hypothesize that PKCλ is involved in 
the growth control of B16 cells, possibly through its control of cell cycle regulatory 
proteins. 
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Figure 16. Time course expression of PKCλ in B16 cells. B16 cells were 
seeded in 60 mm tissue culture dishes at 2.8 × 104/dish. One day after seeding, 
cells were refed with growth media with or without 10 µM RA. At 24, 48, 72 and 
96 hours, cells were prepared for Western blotting as described in Methods. The 
blot was incubated with antibody against total PKCλ, and the bottom half of each 
blot was incubated separately with antibody against GAPDH to correct for protein 
loading.  
A. Western blot.  
B. Relative amount of total PKCλ determined by densitometry with correction for 
the relative amount of GAPDH in each sample.  
C. B16 cells growth curve +/- RA. The logarithmic value of cell number at each 
time point was plotted vs. the time. The slope between two points represents the 
average growth rate between these to two time points. The experiment was 
repeated twice with similar results.
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Cloning of full length mouse PKCλ cDNA: In order to study the role of PKCλ in 
B16 growth control, we cloned the full length mouse PKCλ cDNA into 
pcDNA3.1/V5-His© TOPO® TA Expression vector (see Methods for details). Total 
RNA was isolated from B16 cells and converted to cDNA. Primers specific for 
mouse PKCλ were used to amplify the PKCλ. The size of the amplified mouse 
PKCλ cDNA is 1754bp (Fig. 17).  Because a nonspecific band appeared in the 
PCR product of 30 cycles, the PKCλ PCR product of 25 cycles was used for 
cloning of PKCλ. Then mouse PKCλ was sequenced and confirmed to have the 
identical DNA sequence as the cDNA for murine PKCλ described in Genebank. 
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Figure 17. RT-PCR synthesis of full-length mouse PKCλ cDNA. Total RNA 
was isolated from wild-type B16 cells and converted to cDNA using an RT-PCR 
kit as described in Methods. The cDNA was used as template for PCR using 
primers specific for the PKCλ gene. DNA was amplified for 25 or 30 cycles. 
G3PDH was used as a positive control for PCR reaction. PCR products were 
load in 1% agarose gel. The amplified PKCλ is 1754 bp, located between 1650 
and 2000 bp band on DNA ladder.  
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Selection of sense orientation of PKCλ cDNA: PKCλ cDNA was cloned into 
pcDNA3.1/V5-His© TOPO® TA Expression vector. Two restriction endonucleases, 
Bgl II and Msc I were used to select the sense orientation of PKCλ cDNA. Each 
restriction enzyme cuts once within the PKCλ cDNA and once in the vector. The 
locations of these sites were shown in Figure 18A. If the PKCλ cDNA is in the 
sense orientation, restriction enzyme digestion should yield a 2180 bp Bgl II 
fragment and a 2844bp Msc I fragment (Fig. 18A). Using these diagnostic 
restriction fragments, clone#3 and #4 has the PKCλ in the sense orientation (Fig. 
18B). 
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Figure 18. Restriction enzyme digestion of plasmid containing full length of 
mouse PKCλ cDNA. The PCR product was inserted into pcDNA3.1/V5-His© 
TOPO® TA Expression vector as described in Methods. Double restriction 
enzyme digestion with Bgl II and Msc II was used to select the plasmid with 
PKCλ cDNA in the sense orientation as described in Methods.  
A. Diagram of the double restriction enzyme digestion cutting the pcDNA3.1/V5-
His© TOPO® TA Expression vector containing full length PKCλ. 
B. Electrophoresis result of the enzyme digestion by Bgl II or Msc I.  
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Figure 18 
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Screening for clones with B16 cell overexpression of PKCλ: B16 cells were 
transfected with plasmid containing mouse PKCλ and G418 resistant clones 
were selected for further screening of clones with exogenous PKCλ. The PCR 
upstream primer starts 22 bases before the tranlation start site ATG of mouse 
PKCλ cDNA, and the down stream primer ends 6 bases before the stop codon, 
so the amplified PKCλ could be inserted in frame with the vector DNA sequence 
which encodes the V5 epitope. This feature allowed us to select the exogenous 
PKCλ using an antibody that recognizes the V5-epitope. Two clones, #12 and 
#30 which were V5-epitope positive, were selected as B16 cell clones that 
express exogenous PKCλ (Fig. 19A). Total PKCλ protein levels were then 
detected by Western blot against PKCλ. The Western blot result confirmed that 
clone #12 and #30 overexpressed PKCλ, which is about two-fold increase 
compared to wildtype B16 cell.  Clone #105, a V5-epitope negative clone, had 
lower PKCλ protein level, which is about 70% of the wildtype (Fig. 19B). We used 
clone #105 as a negative control in the phenotype study. 
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Figure 19. Expression of exogenous and total PKCλ protein in B16 clones 
transfected with plasmid encoding the full length mouse PKCλ cDNA. B16 
cells were transfected with plasmid encoding the full length mouse PKCλ cDNA 
fused with the V5 epitope. Clones were selected for their ability to grow in G418. 
One hundred and twenty clones were selected and then tested for the amount of 
exogenous PKCλ protein expressed by Western blotting using anti-V5 antibody.  
– negative control for V5 epitope expression using cell lysate from B16 cells 
transfected with empty vector; + positive for V5 epitope expression using cell 
lysate from the in vitro transcription translation system with the plasmid 
containing the full length mouse PKCλ cDNA. 
A. Expression of PKCλ fusion protein using antibody against V5 epitope.  
B. Expression of total PKCλ in the selected clones using antibody against PKCλ. 
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Figure 19 
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Anchorage-dependent growth in PKCλ overexpressed clones: The growth 
studies showed that cells expressing the exogenous PKCλ (clone #12 and #30) 
had faster rates of growth than untreated wild type B16 cells (P<0.001 and <0.05 
respectively). The growth rate of clone #105 which underexpress PKCλ was 
slower than the wild type B16 cells (P<0.001). Retinoic acid was able to inhibit 
the growth of wildtype and clones that over/underexpress PKCλ. Figure 20 
shows the cell numbers of these clones at 72 h in the presence or absence of RA. 
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 Figure 20. Anchorage-dependent growth in B16 clones over or under-
expressing PKCλ proteins relative to wild-type cells. Cells were seeded in 60 
mm dishes at 2.8 × 105/dish. Triplicate dishes of cells were harvested at 72 h. 
Cell number was measured by using crystal violet dye release described in 
Methods. The data is presented as the mean +/- SEM of triplicate dishes. The 
entire experiment was repeated two additional times with similar results. #12, #30 
- clones overexpressing PKCλ; #105 – clone with low PKCλ protein level relative 
to wild-type cells. (* P<0.05) 
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Anchorage-independent growth in PKCλ overexpressed clones: We 
determined whether altered expression of PKCλ would affect the ability of B16 
cells to grow in an anchorage-independent fashion, as measured by colony 
formation in soft agarose. As can be seen in Figure 21, clone #105, which has 
lower PKCλ protein level relative to the wild type cells, had fewer soft agarose 
colonies compared to wild type or clones overexpressing PKCλ. However, there 
was no significant difference between the number of soft agarose colonies 
formed by wild type cells and the two clones which overexpress PKCλ. 
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 Figure 21. Anchorage-independent growth in B16 clones over/under-
expressing PKCλ proteins relative to wild-type cells. Cells were seeded at 
5,000 cells/dish in growth medium containing 0.3% agarose over a base of 
growth medium containing 1% agarose. The semi-solid phase containing the 
cells was overlaid with growth medium, which was replenished every two days. 
At the end of 10 days of incubation, the colonies greater than 300 µm were 
counted. The data are presented as the mean +/- SEM of triplicate dishes. #12 
and #30 − clones over-expressing PKCλ; #105 − clone expressing lower amount 
of PKCλ. 
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Melanin production in PKCλ overexpressed clones:  Melanin production is a 
differentiated function of melanocytes, which is frequently decreased or lost in 
melanoma, I investigated whether over/under expression of PKCλ would alter 
melanin production in these cells. There was little difference in cellular melanin 
production between the wild-type B16 cells, clones that overexpressed PKCλ, 
and a clone which underexpressed PKCλ. However, the B16 cell clone that 
underexpressed PKCλ had 2-fold increase of melanin released into medium 
compared to wildtype B16 cells and the B16 cell clones that overexpress PKCλ 
(Fig. 22).  
 132
  
 
Figure 22. Melanin production in control and retinoic acid treated wild-type 
and PKCα mutant protein expression clones. Wild-type B16 cells and clones 
expressing the PKCλ proteins were seeded. After 48 h of incubation, cells were 
harvested for cell counts and measurement of intracellular and extracellular 
melanin as described in Methods. Data are presented as the mean +/- SEM of 
triplicate dishes of cells. The entire experiment was repeated two additional times 
with similar results. #12 and #30 − clones overexpressing PKCλ; #105 − clone 
expressing lower amount of PKCλ.  This experiment was repeated twice with 
similar results. (* P<0.001) 
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Expression of cell cycle regulatory proteins in B16 cells: The discoveries 
that PKCλ expression level varies with the B16 cell growth rate, clones 
overexpressing PKCλ clones grow faster than the wild-type B16 cells, and that 
underexpressing PKCλ  grew more slowly led us to investigate the relationship 
between PKCλ expression and cell cycle regulatory proteins. The protein levels 
of cyclin A, cyclin D1, cyclin D2, cdk4, cdk6, p21, and p27 proteins were 
examined in wildtype B16 cells and B16 clones overexpressing PKCλ treated 
with or without retinoic acid. There were no consistent changes in the protein 
levels of these cell cycle regulatory proteins between the wildtypes B16 cells and 
clones overexpressing PKCλ at 48 h. However, there were consistent and large 
changes in the levels of p21 and p27 in retinoic acid-treated vs. control cells. 
There were no consistent changes in the protein levels of cyclin A, cyclin D1, 
cyclin D2, cdc 25, cdk4, and cdk6 between in RA-treated vs. control cells at 48 h. 
A 48-h treatment with RA decreased the protein level of p21 by 50%, whereas 
the level of p27 was increased by about 2 fold compared to the control cells (Fig. 
23).  
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Figure 23. Expression of cell cycle regulatory proteins in wild-type B16 
cells. Cells were treated with 10 µM RA for 48h and cell extracts were prepared 
for Western Blotting as described in Methods. Replicate blots were incubated 
with antibodies that recognize cdk4, cdk6, cyclinD1, cyclinD3, cyclinA, p21 
Waf1/Cip1, and p27 Kip1. The bottom half of each blot was incubated separately 
with antibody against GAPDH to correct for protein loading and specificity for RA-
induced changes. Following development of the signals by chemiluminesence, 
the relative amount of each protein was determined by densitometry with 
correction for the relative amount of GAPDH in each sample. The experiment 
was repeated two additional times with similar results. 
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Time course for retinoic acid-induced changes in the expression of p21 and 
p27. Analysis of the time dependent changes in expression of p21 and p27 
showed that p27 is upregulated by retinoic acid at an early stage (2-4 h) (Fig. 24). 
Expression of p21 decreased with time in both control and treated cultures. RA 
consistently decreased p21 only at the 48 h treatment time. The earliest time 
point of p27 expression change induced by RA is at 2-4 h. The changes seen in 
the cell cycle inhibitors were not caused by the change of PKCλ, since RA does 
not change the PKCλ protein level until 48 h.  It may be possible that PKCλ is the 
downstream effector of a growth regulatory protein. 
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Figure 24. Temporal expression of p21WAF1 and p27Kip1 in control and RA 
treated cells. Cells were treated with 10 µM RA for the indicated times and then 
cell extracts were prepared for Western Blotting as described in Methods. 
Replicate blots were incubated with antibodies that recognize p21 Waf1/Cip1 (A), 
and p27 Kip1 (B). The bottom half of each blot was incubated separately with 
antibody against GAPDH to correct for protein loading and specificity for RA-
induced changes. Following development of the signals by chemiluminesence, 
the relative amount of p21 and p27 was determined by densitometry, with 
correction for the relative amount of GAPDH in each sample. This experiment 
was repeated twice with similar results.  
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Figure 24 
 140
  
Figure 24 
 
 
 141
  
Discussion 
 
In this study, we show that the level of PKCλ protein correlates with B16 
melanoma cell growth rate. I also found that retinoic acid down-regulated PKCλ 
protein expression. Cells transfected with and overexpressing PKCλ had a higher 
rate of proliferation, while a clone of B16 with low expression of PKCλ relative to 
wild-type cells had a lower rate of growth. We also found that the amount of cell 
regulatory proteins p21 and p27 are controlled by retinoic acid. However, altered 
expression of PKCλ did not change the amount of p21 or p27 (data not shown). 
It has been demonstrated that the microinjection of a peptide with the 
sequence of the pseudosubstrate of the atypical PKCs dramatically inhibits 
oocyte maturation (Dominguez et al., 1992), cell proliferation (Berra et al., 1993), 
and NF-κB expression (Dominguez et al., 1993). However, up until this present 
study there were no reports demonstrating that overexpression of PKCλ affects 
cancer cell growth. 
 Dr. Ohno’s group first discovered PKCλ in mouse P19 embryonal 
carcinoma cells, where this isozyme is abundantly expressed (Akimoto et al., 
1994). They have demonstrated that PKCλ is expressed ubiquitously, while the 
other atypical PKC, PKCζ has a more restricted expression. Moreover, they have 
also demonstrated that retinoic acid treatment, which induces the differentiation 
of P19 cells, is accompanied by large increases in PKCα and PKCε mRNAs and 
decreases in PKCλ and PKCγ mRNAs. We also found similar changes in PKC in 
retinoic acid-induced B16 cell growth arrest and differentiation, i.e. the up-
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regulation of PKCα and down-regulation of PKCλ. Several reports found that 
PKCλ is involved in activation of AP-1 transcriptional activity, followed by the 
activation of the MAPK pathway; hence the proliferation of cancer cells (Bonizzi 
et al., 1999; Huang et al., 2000). These pathways need to be examined in our 
clones which over/under express PKCλ. 
We do not know how PKCλ expression is regulated by retinoic acid. It 
could be regulated at the transcriptional level, or posttranslational level. Since the 
sequence of PKCλ promoter is not currently available, we do not know if there is 
a retinoic-acid response element in its promoter region. We need to investigate 
the half life of the PKCλ protein in B16 cells treated with retinoic acid vs. control 
in order to determine if retinoic acid regulates PKCλ protein via a post-
translational mechanism.   
  With the overexpression data and the time course expression profile of 
PKCλ, we thought there may be a link between PKCλ and cell cycle regulators. 
We examined the expression of cell cycle regulatory proteins in clones which 
overexpressed PKCλ. However, there are no consistent changes in the levels of 
cyclins, cdks or cdk inhibitors in wild type vs. PKCλ overexpressing clones. 
These data may indicate that PKCλ does not directly regulate the cell cycle. 
However, we found that retinoic treatment of wild type cells consistently 
increased p27 expression and down-regulated p21 expression. Both p21 and 
p27 are the members of Waf/Kip cell cycle inhibitor family. 
There is a retinoic acid response element in the p21 promoter, and retinoic 
acid increases p21 mRNA and protein levels in many cell lines (Lavelle et al., 
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1999; Suzui et al., 2000). However, the down regulation of p21 by retinoic acid in 
B16 cells is a consistent finding. I have also found that RA inhibits p21 
expression in B16 clones overexpressing PKCλ. Changes of p21 expression 
induced by retinoic acid treatment at times earlier than 48-h are not large or 
consistent. Immunoreactive p21 appears as a doublet on the Western blot (Fig. 
23 and Fig. 24A). It is most likely that the upper band represents phosphorylated 
p21. Sheaff et al. (1997) has reported that p27 can be phosphorylated, but there 
have been no reports of phosphorylated p21. The nature of this doublet needs to 
be investigated by using phosphatase to determine if removing phosphate 
collapses the doublet into one band. 
Our finding that RA decreases p21 expression in B16 melanoma cells is at 
odds with numerous reports showing that RA increases expression of p21. Hsu 
et al. (2000) has reported that retinoic acid treatment up-regulated p27 and 
down-regulated p21 in human lung squamous carcinoma cells, similar to the 
results described above for B16 cells.  It is well established that retinoic acid 
inhibits B16 cell growth and p21 is a cyclin kinase inhibitor, but the importance of 
down-regulation of p21 by retinoic acid treatment is unknown. One possible 
explanation is that p21 is mutated in the B16 cell line as a result of carcinogenic 
process. Mutations in the p21 and p27 genes are rare (Nakayama et al., 1996) 
and the most often seen mutations in CKIs are the mutations of p16 genes, as 
found in familial melanomas and other cancers (reviewed by Sherr and Roberts, 
1999). However, p21 has been shown to have polymorphisms in sporadic 
melanoma within the Japanese population (Konishi et al., 2000). Moreover, p21 
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is highly overexpressed in human squamous cell carcinomas compared to 
adjacent benign epithelium (Tron et al., 1996), and its expression is increased in 
advanced primary melanomas compared with benign lesions such as common 
acquired nevi (Trotter et al., 1997). High levels of p21 are associated with chemo 
resistance in myelogenous leukemias (Zhang et al., 1995). The significance of 
high levels of p21 in melanomas is not clear. If overexpression of p21 is 
associated with the melanoma phenotype, then a decrease in melanoma cells 
which lose this phenotype, such as RA treated cells would be a logical finding. 
Another possible explanation is that p21 interacts with cyclin D and stabilizes the 
complex (Cheng et al., 1999). A decrease in p21 induced by retinoic acid may 
destabilize the p21-cyclin D complex, thereby interfering with cell cycle 
progression. Further studies need to be done to explore the importance of this 
reduction of p21 by retinoic acid in B16 cells. Lastly, there is a reciprocal 
relationship between p27 and p21, in that an increase of p27 is associated with a 
decrease of p21 (Matyak et al., 1999; D’Agnano et al., 2001). 
An increase in the level of p27 protein subsequent to treatment with 
retinoic acid has been reported for several cell lines and tumor cell types (Hsu et 
al., 2000; Zhang et al., 2001; Nakamura et al., 2003). Most of the studies found 
that the RA-induced increase in p27 was independent of the retinoic acid 
receptor. However, in one study it was reported that introduction of RAR induced 
the expression of p27 (Hayashi et al., 2001). Previous reports showed that p27 
mRNA levels were not changed by retinoic acid treatment, whereas the 
degradation of p27 through the ubiquitination pathway is decreased by retinoic 
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acid treatment. It is likely that the increase of p27 inhibits the ability of cyclin-cdk 
complexes to phosphorylate the Rb protein. Hypophosphorylated Rb will prevent 
cells from entering into the S phase of the cell cycle. The earliest time point that 
an increase of p27 protein is seen is 2-4h after retinoic acid treatment, 
suggesting that p27 is directly regulated by retinoic acid. We will need to 
determine p27 mRNA levels and the half-life of the p27 protein in control vs. RA 
treated cells to gain further insight into how RA regulates p27 expression.  
PKCλ/ι protects human K562 leukemia cells against taxol-induced 
apoptosis (Murray and Fields, 1997). Phosphorylation of ATF-2 a member of AP-
1 family, which is required for activity, was significantly reduced after 48-h of 
retinoic acid treatment (Huang and Niles, unpublished data). High expression of 
ATF-2 renders melanoma resistant to chemotherapeutic drugs, such as taxol 
(Hayakawa et al., 2003).  We found the phosphorylated ATF-2 level was higher 
in clones overexpressing PKCλ compared to a clone underexpressing PKCλ 
(data not shown). Additionally, phospho-Erk1/2 was also increased in PKCλ 
overexpressing vs. underexpressing clones. These data indicate that PKCλ may 
increase cell proliferation via activation of the MAPK pathway. Also PKCλ 
overexpression increases ATF-2 phosphorylation, which may result in 
maintenance of cell survival and resistance to drug induced apoptosis. 
Recent studies have elucidated the important role of PKCλ in the 
establishment or maintenance of cell polarity (Suzuki et al., 2001; Nagai-Tamai et 
al., 2002). This function of PKCλ might be related to the much higher amount of 
melanin released into the medium from the PKCλ underexpressing clone despite 
 146
  
their low cell density. PKCλ appears to be important in maintaining tight junctions 
and cell-cell adhesion. 
PKCλ and PKCζ are both members of the atypical PKCs and have 
common structures and functions. Both are involved in cell skeleton, however, 
PKCζ knock-out mice are viable showing impaired NFκB signaling and immune 
response (Leitges et al., 2001; Martin et al., 2002), whereas PKCλ/ι knock-out 
mice die at an early embryonic stage (Akimoto et al., unpublished result). 
Overexpression of PKCι (the human homolog of PKCλ) leads to increased 
resistance to okadaic acid-induced apoptosis, whereas overexpression of PKCζ 
has no protective effect (Murray and Fields, 1997). Retinoic acid only down-
regulates PKCλ, not PKCζ, which indicates that these two members of aPKCs 
have different functions.  
Retinoic acid up-regulates PKCα and down-regulates PKCλ expression. 
Also overexpression of PKCα inhibits B16 cell growth while overexpression of 
PKCλ promotes B16 cell proliferation. These data indicate that PKCα and PKCλ 
have opposing actions on B16 cell growth. Weichert et al. (2003), using clinical 
ovarian tissue specimens, demonstrated a significant negative correlation of 
PKCα level with histopathological grading and a significant positive correlation of 
PKCι, the human counterpart of PKCλ, with histopathological grading. PKCι 
expression was only detected in primary ovarian carcinoma and recurrent cases, 
but not in normal and borderline ovarian tissues. Expression of PKCι correlated 
with shorter patients’ survival time. These data suggest that alteration of PKC 
isoform expression (decrease of PKCα and increase of PKCι) may be involved in 
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the progression of ovarian carcinomas (Weichert et al., 2003). Furthermore, long 
term treatment of B16 cells with PDB induces increased cell growth and 
decreased melanin production (see part I of thesis), while it down-regulates 
PKCα and upregulates PKCλ (data not shown). A 24-h treatment of B16 cells 
with PDB substantially increases the PKCλ protein level. Whether the increase of 
PKCλ by PDB is directly linked to the decrease in PKCα is not known and these 
possibilities are currently under investigation. 
We tried to further investigate the role of PKCλ in B16 cell proliferation by 
expressing a dominant-negative PKCλ mutant. However, transfection with this 
construct did not yield any G418 resistant colonies. These results suggest that 
PKCλ might essential for B16 cell proliferation. In future study, a conditional 
expression vector will be used for the dominant-negative PKCλ to circumvent this 
negative selection problem. 
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Summary and Conclusions 
 
Retinoids have been used in many clinical trials for prevention and 
treatment of certain types of malignancies. The toxicity and resistance of some 
tumors to retinoids make it necessary to investigate the mechanism of retinoids’ 
action in order to develop more effective strategies for chemo-prevention and 
treatment of tumors.  Retinoic acid induces B16 melanoma cell growth arrest and 
differentiation. The expression pattern of the PKC isozymes in these melanoma 
cells is changed by retinoic acid. PKCα level is increased 8-12 fold, while PKCλ 
expression is decreased by 50%. Overexpression of PKCα and PKCλ increases 
or decreases the growth rate of B16 cell respectively, which indicates that these 
PKC family members play a role in RA induced B16 cell growth arrest and 
differentiation. Discrepancies between the level of PKCα protein and its 
associated enzyme activity led us to investigate the possible role of non-
enzymatic effect of PKCα. 
From the work on PKCα, the conclusions are:  
1. Decrease in PKCα enzyme activity by bisindolylmaleimide treatment does 
not counteract the action of retinoic acid in B16 cells. 
2. Down-regulation of PKCα protein by phorbol dibutyrate does counteract 
the action of retinoic acid in B16 cells. 
3. Overexpression of dominant-negative PKCα mimicks retinoic acid’s action 
on growth arrest and induction of AP-1 activity. 
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4. Over-expression of dominant-negative PKCα does not alter the expression 
and activity of other PKC isozymes expressed in B16 cells. 
 
From the work on PKCλ, the conclusions are: 
1. The PKC isozymes expressed in B16 cells are PKCα, δ, ε, ζ, λ, and µ. 
2. PKCα is the only PKC up-regulated by RA, and RA treatment down-
regulates PKCλ and PKCµ in B16 cells. 
3. The expression level of PKCλ correlates with B16 cell growth rate, i.e., the 
higher the growth rate, the more PKCλ expressed. 
4. Overexpression of full length wild type PKCλ increases B16 cell growth 
rate. 
5. Cell cycle regulatory proteins are not altered by overexpression of PKCλ. 
6. Retinoic acid treatment down-regulates p21 and up-regulates p27 
expression in B16 cells. 
7. Down-regulation of p21 is a delayed response to RA and upregulation of 
p27 is an early response to RA. 
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Future Study 
 
 
Although our work on PKCα indicates that PKCα has non-enzymatic 
functions, more work needs to be done to prove this hypothesis. Since we failed 
to down-regulate PKCα by using antisense RNA, we can use the siRNA method 
to accomplish this goal. This technology has been demonstrated to be a more 
effective approach to down-regulating a specific protein. The most direct way to 
prove that PKCα has a non-enzymatic function is to identify the proteins that 
PKCα interacts with in the nucleus. This goal can be accomplished by using a 
yeast two-hybrid system to identify PKCα binding partners. 
There have been few published reports on the regulation and function of 
PKCλ. I was the first investigator to demonstrate a connection between PKCλ 
and retinoic acid. It will be important to determine how retinoic acid regulates 
PKCλ expression, and the role of PKCλ in the RA-induced signal transduction 
pathway. Use of a cDNA construct encoding dominant-negative PKCλ will allow 
us to determine the role of PKCλ in growth. In preliminary studies, clones 
expressing DN-PKCλ did not survive. To circumvent this possible lethal effect of 
DN-PKCλ, future studies will use the conditional expression approach to study 
the role of PKCλ. 
Other aspects that need to be clarified regarding the function of PKCλ and 
cell cycle regulators include: 
1) The relation between PKCλ and MAPK pathway. 
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2) Half life of the p21 and p27 protein in control vs. RA treated B16 
melanoma cells. 
3) Activity of cyclin/cdk complexes in control vs. RA treated B16 cells.  
4) The importance of RA-induced down-regulation of p21 in the control of 
B16 cell proliferation RA treatment. 
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